|
Akeso, Inc. is a biopharmaceutical company engaged in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on major disease areas including oncology, autoimmune diseases, respiratory diseases, central nervous system disorders, inflammation, and metabolic diseases. Its core technology platform centers on bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), T-cell engagers (TCEs), siRNA, cell therapy, and mRNA. Key commercialized products include cadonilimab, a PD-1/CTLA-4 bispecific antibody, and ivosideb, a PD-1/VEGF bispecific antibody. The company also markets inutuximab, ifosideb, and gumosideb for non-oncology indications. Akeso operates through subsidiaries such as CTTQ-Akeso and Akeso Biopharma, and maintains a joint venture with Chia Tai Tianqing for the exclusive sales and contract manufacturing of its monoclonal antibody products in the PRC. The company has licensed overseas rights for ivosideb to Summit Therapeutics and has received FDA approval for penpulimab for nasopharyngeal carcinoma. Akeso was founded in 2012 and listed on the main board of the Stock Exchange of Hong Kong in 2020. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Biotechnology | Homepage akesobio.com |
| Sector Healthcare | IR page akesobio.com/cn/investor-relations/financial-reports | |
|
Tags
bispecific antibodies, oncology, antibody-drug conjugates, t-cell engagers, sirna, cell therapy, mrna, autoimmune diseases, respiratory diseases, central nervous system, metabolic diseases, pd-1/ctla-4, cadonilimab, ivosideb, inutuximab, ifosideb, gumosideb, penpulimab, CTTQ-Akeso, Akeso Biopharma, Chia Tai Tianqing, LYG Tianqing, Nanjing Tianqing, Summit Therapeutics, ACE Platform
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 57.4B |
| Market cap (USD) | $ 7.315B |
| P/E | -50.43 |
| PEG | — |
| P/BV | 5.60 |
| P/S | 14.13 |
| P/OCF | -113.46 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | 1.1% |
| Returns | |
|---|---|
| ROE | -14.2% |
| ROI | -11.7% |
| ROIC | -11.7% |
| Profit margin | -36.4% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 11.7% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -68.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Podcast Mentions
Announcements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
2026-10-25
HONG KONG, Oct. 25, 2026 -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase III HARMONi-GI1 trial (AK112-309). The study evaluated first-in-class ivonescimab plus chemotherapy versus durvalumab (PD-L1) plus chemotherapy as first-line treatment for patients with advanced biliary tract cancer (BTC) and was presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.
In a prespecified interim analysis reviewed by the Independent Data Monitoring Committee (IDMC), HARMONi-GI1 met its primary endpoint of overall survival (OS), with the ivonescimab plus chemotherapy arm demonstrating statistically significant and clinically meaningful improvement over the control arm. The trial also met all key secondary endpoints, including progression-free survival (PFS) and objective response rate (ORR).
On the strength of these findings, HARMONi-GI1 was selected as a Late-Breaking Abstract (LBA) for oral presentation and included in the official ESMO press program. Principal investigator Professor Jian Zhou, Academician of the Chinese Academy of Sciences, President of Zhongshan Hospital, Fudan University, presented the detailed clinical results of this study to the global oncology community during Presidential Symposium II.
Durvalumab combined with chemotherapy is currently the preferred first-line immunotherapy regimen recommended by both domestic and international guidelines and is widely regarded as the standard of care. HARMONi-GI1 is the first Phase III trial in biliary tract cancer to demonstrate statistically significant and clinically meaningful positive results in overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) versus this standard of care regimen (PD-L1 monoclonal antibody plus chemotherapy), marking a major milestone in the treatment of this challenging disease.
The results showed that, compared with durvalumab plus chemotherapy, first-line treatment with ivonescimab plus chemotherapy significantly prolonged overall survival in patients with BTC, meeting the prespecified threshold for statistical significance and delivering clinically meaningful benefit. Prespecified subgroup analyses showed a generally consistent trend of OS benefit.
ITT Population: Median OS of 14.9 Months with a 25% Reduction in the Risk of Death, Demonstrating a Significant Long-Term Survival Tail Effect
In the intent-to-treat (ITT) population, ivonescimab plus chemotherapy significantly prolonged overall survival compared with durvalumab plus chemotherapy. Median OS was 14.9 months versus 12.1 months (HR=0.75; 95% CI: 0.61–0.92), corresponding to a 25% reduction in the risk of death (P=0.0031). (For reference, the TOPAZ-1 study published in 2022 reported a median OS of 12.8 months with durvalumab plus chemotherapy versus 11.5 months with chemotherapy alone [HR=0.80]; based on the outcome of that trial, durvalumab plus chemotherapy became an international first-line standard of care.)
The survival benefit with ivonescimab continued to widen over time relative to the control arm, reflecting a more durable and clinically meaningful long-term survival advantage. Twelve-month OS rates were 59.7% versus 50.7%, and 18-month OS rates were 44.0% versus 32.5%, underscoring a pronounced long-term survival tail effect in the ivonescimab arm.
Following study discontinuation, a substantially lower proportion of patients in the ivonescimab arm received any anti-tumor therapy compared with the durvalumab arm (31.8% versus 45.9%).
ITT Population: Ivonescimab Significantly Prolonged PFS, with a Median PFS of 8.4 Months and a 39% Reduction in the Risk of Disease Progression or Death
The study met its key secondary endpoint of progression-free survival. In the ITT population, ivonescimab significantly prolonged PFS compared with durvalumab, with a median PFS of 8.4 months versus 5.8 months (HR=0.61; 95% CI: 0.51–0.72; P<0.0001). The 6-month PFS rates were 68.7% versus 49.3%, and nine-month PFS rates were 49.3% versus 31.7% for the ivonescimab and durvalumab arms, respectively.
ITT Population: Ivonescimab Demonstrated Robust and Deep Tumor Responses
The study also met its key secondary endpoint of objective response rate. Ivonescimab showed superior depth of tumor response and disease control compared with durvalumab. ORR was 53.8% versus 32.5%, an absolute difference of 21.3 percentage points (P<0.0001). Disease control rates (DCR) were 91.5% and 77.8%, respectively.
Consistent OS and PFS Benefits Across Subgroups with Ivonescimab
Among patients with an ECOG performance status of 1 (ECOG PS 1), ivonescimab demonstrated a significant survival benefit versus durvalumab (OS HR, 0.71 [95% CI, 0.56–0.91]; PFS HR, 0.57 [95% CI, 0.47–0.70]). Similarly, among older patients (aged ≥65 years), ivonescimab showed a significant survival benefit compared with durvalumab (OS HR, 0.67 [95% CI, 0.47–0.95]; PFS HR, 0.53 [95% CI, 0.39–0.71]).
Favorable Overall Safety Profile with No New Safety Signals
The safety profile of ivonescimab plus chemotherapy was manageable, accompanied by longer treatment exposure. The most common adverse events of any grade and of grade 3/4 were hematologic toxicities; no new safety signals were identified.
Incidences of serious adverse events (43.4% versus 43.7%) and of bleeding events of any grade (9.7% versus 6.5%) or grade ≥3 (1.5% versus 1.8%) were similar to those in the durvalumab arm, with no evidence of increased risk of uncontrolled bleeding.
Biliary tract cancer is a highly heterogeneous malignancy arising from the bile ducts and gallbladder and carries a poor prognosis; approximately 50% of patients are diagnosed at an advanced stage, with survival typically less than one year. PD-1/L1 inhibitor plus chemotherapy is the established international first-line treatment for advanced biliary tract cancer, yet the overall survival benefit remains limited. Durvalumab plus chemotherapy is currently regarded as the preferred first-line immuno-oncology regimen recommended by both domestic and international guidelines.
The breakthrough data from HARMONi-GI1 strongly support the potential of ivonescimab plus chemotherapy as a new standard of care for first-line advanced BTC. Furthermore, as the first Phase III study to achieve a positive result in gastrointestinal cancers following multiple Phase III successes in lung cancer, HARMONi-GI1 marks the expansion of ivonescimab's breakthrough clinical value from lung cancer into a broader range of solid tumors. Ivonescimab plus chemotherapy for first-line BTC has been proposed for Priority Review designation by China's National Medical Products Administration (NMPA).
On October 21, 2026, Summit announced a clinical trial collaboration with ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy in a registration-enabling Phase II/III study (EA2251), in the first-line treatment of patients with advanced BTC.
About Ivonescimab
Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody independently developed by Akeso. It is the world's first approved bispecific antibody that combines immuno-oncology and anti-angiogenesis mechanisms in a single molecule, helping to define a new generation of bispecific immuno-oncology therapies. Ivonescimab is also the first therapy to demonstrate positive results in a Phase III head-to-head study against pembrolizumab.
Building on its strong clinical profile in the IO2.0 landscape, Akeso is advancing a comprehensive global development program for ivonescimab across multiple tumor types and treatment settings. As a cornerstone of the Company's IO2.0 + ADC2.0 strategy, ivonescimab aims to help reshape standards of care in major cancers worldwide.
More than 18 Phase III studies of ivonescimab are underway globally, including seven international multi-regional registrational Phase III trials and seven head-to-head studies versus PD-1/PD-L1 therapies. These programs encompass eight registrational or Phase III studies in lung cancer, as well as trials in first-line MSS/pMMR colorectal cancer, first-line PD-L1-positive head and neck squamous cell carcinoma (in combination with ligufalimab versus pembrolizumab), first-line biliary tract cancer (versus pembrolizumab/ durvalumab-based regimen), first-line triple-negative breast cancer, first-line pancreatic cancer, and first-line urothelial carcinoma (versus pembrolizumab plus a Nectin-4 ADC).
Akeso has out-licensed the exclusive rights to develop and commercialize ivonescimab in the United States and Canada, South America, Europe, the Middle East, Africa, and Japan to Summit Therapeutics under an agreement with a total potential value of up to US$5 billion.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.
Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
2026-10-21
-
Becomes the 7th International Registrational Clinical Trial for Ivonescimab
-
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
Hong Kong, October 21, 2026 – Akeso, Inc. (HKEX: 9926.HK) today announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab in a registration-enabling Phase II/III study in biliary tract cancer (BTC). The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy in the first-line treatment of patients with advanced BTC.
This marks the 7th international registrational Phase II/III clinical trial for ivonescimab. Previously, the Phase III HARMONi-GI1 study conducted by Akeso in China, evaluating ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for patients with BTC, achieved a positive overall survival (OS) result that was both statistically significant and clinically meaningful.
“Biliary tract cancer is often diagnosed at an advanced stage, and despite recent progress, there is a need for more effective first-line options that can extend survival and improve disease control,” said lead investigator Deirdre J. Cohen, MD, MS, Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, Director of the Gastrointestinal Oncology Program for the Mount Sinai Health System and Co-Director of the Center of Excellence for Pancreatic Cancer at the Mount Sinai Tisch Cancer Center. “EA2251 will explore a novel therapeutic approach in the front-line setting by evaluating ivonescimab with chemotherapy against current immunotherapy-based standards of care.”
“We are delighted to see the global clinical development of ivonescimab further expand into the field of biliary tract cancer. Against the background of the positive OS results from the Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy versus durvalumab plus chemotherapy, the advancement of the Phase III EA2251 study by a leading cooperative oncology group in the United States further strengthens our confidence in achieving global success,” said Dr. Michelle Xia, Founder, Chairwoman, President and Chief Executive Officer of Akeso. “We look forward to the progress of ivonescimab’s registrational clinical development worldwide and its potential to become a superior treatment option for patients with biliary tract cancer globally as early as possible.”
“We are honored to collaborate with ECOG-ACRIN on EA2251 as we continue to expand the development program for ivonescimab in areas of meaningful unmet need,” said Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics. “The sponsorship and conduct of this registration-enabling study by a leading cooperative oncology group underscores the scientific interest in evaluating ivonescimab in difficult-to-treat cancers, including BTC, and supports Summit’s commitment to building a robust body of clinical evidence across multiple tumor types and treatment settings.”
EA2251 is the second Phase III registrational clinical study of ivonescimab in BTC. Detailed results from HARMONi-GI1 (AK112-309), which evaluated ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with BTC, will be presented at the European Society for Medical Oncology 2026 Congress (ESMO 2026) on Sunday, October 25, during the Presidential Symposium from 4:30pm – 6:15pm CET (11:30am – 1:15pm EDT).
About ECOG-ACRIN
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is one of the world’s leading scientific organizations, known for innovative multicenter clinical trials involving adults with cancer or at risk of developing it. Its expansive membership network includes over 1,400 hospitals and cancer centers across the United States and around the world, involving nearly 21,000 research professionals and advocates. To learn more, visit www.ecog-acrin.org
and follow ECOG-ACRIN on X
, YouTube
, and BlueSky
, or call 215-789-3631.
About Ivonescimab
Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody independently developed by Akeso. It is the world’s first approved bispecific antibody that combines immuno-oncology and anti-angiogenesis mechanisms in a single molecule, helping to define a new generation of bispecific immuno-oncology therapies. Ivonescimab is also the first therapy to demonstrate positive results in a Phase III head-to-head study against pembrolizumab.
Building on its strong clinical profile in the IO2.0 landscape, Akeso is advancing a comprehensive global development program for ivonescimab across multiple tumor types and treatment settings. As a cornerstone of the Company’s IO2.0 + ADC2.0 strategy, ivonescimab aims to help reshape standards of care in major cancers worldwide.
More than 18 Phase III studies of ivonescimab are underway globally, including 7 international multi-regional registrational Phase III trials. These programs encompass eight registrational or Phase III studies in lung cancer, as well as trials in first-line MSS/pMMR colorectal cancer, first-line PD-L1-positive head and neck squamous cell carcinoma (in combination with ligufalimab versus pembrolizumab), first-line biliary tract cancer (versus a durvalumab-based regimen), first-line triple-negative breast cancer, first-line pancreatic cancer, and first-line urothelial carcinoma (versus pembrolizumab plus a Nectin-4 ADC).
Akeso has out-licensed the exclusive rights to develop and commercialize ivonescimab in the United States and Canada, South America, Europe, the Middle East, Africa, and Japan to Summit Therapeutics under an agreement with a total potential value of up to US$5 billion.
About AkesoAkeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.
2026-10-19
HONG KONG, Oct. 19, 2026 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") and its partner Summit Therapeutics Inc. (NASDAQ: SMMT) jointly announced an international multicenter Phase II clinical study (SMT112-216 / AK112-216 / NCT07877194).
Built on Akeso’s first-in-class immuno-oncology (IO) cornerstone therapy ivonescimab (PD-1/VEGF bispecific antibody), the study will assess the efficacy and safety of multiple treatment regimens, including the combination of ivonescimab with Akeso’s first-in-class bispecific antibody cadonilimab (PD-1/CTLA-4 bispecific antibody), in previously untreated patients with advanced clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer. Participants will be randomized to receive ivonescimab in combination with cadonilimab, ivonescimab in combination with ipilimumab, ivonescimab monotherapy, or the established international standard-of-care comparator regimen of nivolumab plus ipilimumab.
Cadonilimab is the world’s first approved immuno-oncology bispecific antibody and the only PD-1/CTLA-4 bispecific antibody to have received regulatory approval. It is currently approved for three indications: first-line gastric cancer, first-line cervical cancer, and recurrent or metastatic cervical cancer.
Cadonilimab is being evaluated in 13 Phase III/registrational clinical studies, including two international multicenter trials. In addition, dozens of Phase I/II studies have been conducted across more than 30 tumor types, including renal cell carcinoma, demonstrating robust anti-tumor activity and a favorable safety profile.
Currently, regimens combining a PD-1 inhibitor with a CTLA-4 inhibitor, such as nivolumab plus ipilimumab, and those combining a PD-1 inhibitor with a tyrosine kinase inhibitor (TKI), such as pembrolizumab plus axitinib, represent established first-line standards of care for advanced renal cell carcinoma internationally. Building on ivonescimab as a cornerstone therapy, combinations with the next-generation IO agent cadonilimab, a PD-1/CTLA-4 bispecific antibody, and additional agents will allow further exploration of the synergistic, complementary and differentiated effects across distinct targets and mechanisms of action. This approach has the potential to further improve clinical benefit and offer patients with advanced renal cell carcinoma more diverse and precise novel treatment options.
Early clinical studies have shown that both cadonilimab and ivonescimab demonstrate promising antitumor activity with manageable safety profiles in renal cell carcinoma, providing a strong rationale for further evaluation of their combination in advanced disease.
Earlier this year, Summit announced a clinical trial collaboration to evaluate the safety and efficacy of ivonescimab in combination with casdatifan, a HIF2α inhibitor from Arcus Biosciences, in ccRCC, including first-line metastatic disease.
About AkesoAkeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.
Forward-Looking StatementsThis announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
FF305 Next Day Disclosure Return (Equity issuer - changes in issued shares or treasury shares, share buybacks and/or on-market sales of treasury shares) Instrument:
Equity issuer
Name of Issuer:
Akeso, Inc.
Date Submitted:
16 October 2026
Status:
New Submission
Section I must be completed by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable pursuant to rule 13.25A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Exchange”) (the “Main Board Rules”) or rule 17.27A of the Rules Governing the Listing of Securities on GEM of the Exchange (the “GEM Rules”). Section I
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
09926
Description
Listed on the Exchange
Not applicable
Yes
A. Changes in issued shares or treasury shares Changes in issued shares (excluding treasury shares) Events
Opening balance as at (Note 1) 1).
30 September 2026
Placing/subscription - new shares involved
Changes in treasury shares
As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3)
Number of issued shares (excluding treasury shares)
921,143,176 20,000,000
Issue/ selling price per share (Note 4)
Number of treasury shares
0 2.17 %
Total number of issued shares
921,143,176 HKD
97.76
Issue of shares upon completion of placing of new shares under general mandate pursuant to the placing agreement dated 14 October 2026 (details of which were disclosed in the announcements of the Company dated 14 and 16 October 2026) Date of changes
16 October 2026
Closing balance as at (Notes 5 and 6) 16 October 2026
941,143,176
Page 1 of 6
0
941,143,176
v 1.3.0
FF305 B. Shares redeemed or repurchased for cancellation but not yet cancelled as at the closing balance date (Notes 5 and 6)
Page 2 of 6
Not applicable
v 1.3.0
FF305 Confirmation Pursuant to Main Board Rule 13.25C / GEM Rule 17.27C, we hereby confirm to the best knowledge, information and belief that, in relation to each issue of shares or sale or transfer of treasury shares as set out in Section I, it has been duly authorised by the board of directors of the listed issuer and carried out in compliance with all applicable listing rules, laws and other regulatory requirements and, insofar as applicable: (Note 7) (i)
all money due to the listed issuer in respect of the issue of shares, or sale or transfer of treasury shares has been received by it;
(ii)
all pre-conditions for the listing imposed by the Main Board Rules / GEM Rules under "Qualifications of listing" have been fulfilled;
(iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled; (iv) all the securities of each class are in all respects identical (Note 8); (v)
all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with all other legal requirements;
(vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue, sale or transfer; (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies. Notes to Section I: 1.
Please insert the closing balance date of the last Next Day Disclosure Return published pursuant to Main Board Rule 13.25A / GEM Rule 17.27A or Monthly Return pursuant to Main Board Rule 13.25B / GEM Rule 17.27B, whichever is the later.
Please set out all changes in issued shares or treasury shares requiring disclosure pursuant to Main Board Rule 13.25A / GEM Rule 17.27A together with the relevant dates of changes. Each category will need to be disclosed individually with sufficient information to enable the user to identify the relevant category in the listed issuer's Monthly Return. For example, multiple issues of shares as a result of multiple exercises of share options under the same share option scheme or of multiple conversions under the same convertible note must be aggregated and disclosed as one category. However, if the issues resulted from exercises of share options under 2 share option schemes or conversions of 2 convertible notes, these must be disclosed as 2 separate categories.
The percentage change in the number of issued shares (excluding treasury shares) of the listed issuer is to be calculated by reference to the opening balance of the number of issued shares (excluding treasury shares) being disclosed in this Next Day Disclosure Return.
Page 3 of 6
v 1.3.0
FF305 4.
In the case of a share repurchase or redemption, the “issue/ selling price per share” shall be construed as “repurchase price per share” or “redemption price per share”. Where shares have been issued/ sold/ repurchased/ redeemed at more than one price per share, a volume-weighted average price per share should be given.
The closing balance date is the date of the last relevant event being disclosed.
For repurchase or redemption of shares, disclosure is required when the relevant event has occurred (subject to the provisions of Main Board Rules 10.06(4)(a), 13.25A and 13.31 / GEM Rules 13.13(1), 17.27A and 17.35), even if the repurchased or redeemed shares have not yet been cancelled. If repurchased or redeemed shares are to be cancelled upon settlement of such repurchase or redemption after the closing balance date, they shall remain part of the issued shares as at the closing balance date in Part A. Details of these repurchased or redeemed shares shall be disclosed in Part B.
Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases.
“Identical” means in this context:
the securities are of the same nominal value with the same amount called up or paid up;
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Page 4 of 6
v 1.3.0
FF305 Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under Main Board Rule 10.06(4)(a) / GEM Rule 13.13(1).
Repurchase report
Not applicable
Page 5 of 6
v 1.3.0
FF305 Section III must also be completed by a listed issuer where it has made a sale of treasury shares on the Exchange or any other stock exchange on which the issuer is listed which is discloseable under Main Board Rule 10.06B / GEM Rule 13.14B.
Report of on-market sale of treasury shares
Not applicable
Submitted by: XIA Yu (Name) Title: Director (Director, Secretary or other Duly Authorised Officer)
Page 6 of 6
v 1.3.0
2026-10-10
HONG KONG, Oct. 10, 2026 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in the neoadjuvant/adjuvant (perioperative) treatment of resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.
This marks a significant new indication for cadonilimab beyond gastric, lung, and cervical cancers, and represents the 13th Phase III/registrational study of the therapy conducted globally. Cadonilimab has moved from later-line to first-line treatment of advanced disease and is now being evaluated in the perioperative setting, further broadening its clinical footprint in immuno-oncology (IO) 2.0.
Colorectal cancer is among the malignancies with the highest incidence and mortality worldwide, with colon cancer accounting for most cases. Perioperative outcomes are a major determinant of long-term prognosis. Patients with MSI-H/dMMR colon cancer derive limited benefit from conventional perioperative chemotherapy, with pathological response rates of only approximately 7%—a persistent and significant unmet medical need.
In metastatic MSI-H/dMMR colorectal cancer, immune checkpoint inhibitors are already established as the standard of care. In localized disease, perioperative treatment holds the potential for curative intent and the prospect of durable clinical cure—an area of substantial clinical importance and patient value. While multiple exploratory studies of PD-(L)1 monoclonal antibodies in this setting have shown encouraging efficacy signals, no immunotherapy has yet been approved anywhere for the perioperative treatment of localized MSI-H/dMMR colon cancer.
MSI-H/dMMR colon cancer is highly responsive to immunotherapy due to its high tumor mutational burden and inflamed immune microenvironment. However, single-target immune checkpoint inhibitors still leave room for improved outcomes. By dual blockade of the PD-1 and CTLA-4 pathways, cadonilimab is designed to more effectively activate and sustain antitumor immune responses in the perioperative setting. This approach has the potential to increase rates of major pathological response (MPR) and pathological complete response (pCR), thereby lowering the risk of postoperative recurrence and improving long-term survival.
Supporting evidence comes from a prior Phase II study of cadonilimab monotherapy as neoadjuvant treatment in patients with MSI-H/dMMR colorectal cancer. Data presented at the 2024 ESMO Immuno-Oncology Congress showed a pathological complete response (pCR) rate of 84.6% and a major pathological response (MPR) rate of 100% among patients who proceeded to surgery, with a manageable safety profile.
As the first approved checkpoint bispecific antibody for cancer, cadonilimab has shown consistent clinical benefit across a broad range of patients, including both PD-L1-positive and PD-L1-negative individuals, in extensive real-world use and multiple Phase III trials. It is increasingly recognized as a foundational therapy in the immuno-oncology (IO) 2.0 era. Cadonilimab is currently being evaluated in 13 Phase III/registrational studies worldwide across major indications such as lung, gastric, cervical, liver and colon cancers, spanning first-line, second-line, perioperative, adjuvant and consolidation settings.
About Cadonilimab
Cadonilimab is a first-in-class PD-1/CTLA-4 bispecific antibody developed by Akeso for cancer immunotherapy. In June 2022, it received initial marketing approval from China's National Medical Products Administration (NMPA) for the treatment of patients with relapsed or metastatic cervical cancer who had progressed on or after platinum-based chemotherapy. In September 2024, cadonilimab was approved in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. In May 2025, cadonilimab plus platinum-based chemotherapy, with or without bevacizumab, was approved for the first-line treatment of persistent, recurrent, or metastatic cervical cancer.
By simultaneously targeting PD-1 and CTLA-4, cadonilimab delivers synergistic antitumor activity. It has shown robust efficacy with markedly lower toxicity and improved tolerability compared with conventional combination regimens, demonstrating potent activity across multiple tumor types independent of PD-L1 expression and offering breakthrough clinical value in immunotherapy-resistant and "cold" tumors.
To date, cadonilimab has been evaluated in more than 40 clinical studies spanning over 20 indications, including gastric, lung, liver, cervical, and pancreatic cancers. Thirteen Phase III/registrational studies are ongoing; three have met their primary endpoints; and two global Phase III/registrational trials are advancing.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.
FF301
Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities For the month ended:
30 September 2026
Status: New Submission
To : Hong Kong Exchanges and Clearing Limited Name of Issuer:
Akeso, Inc.
Date Submitted:
07 October 2026
I. Movements in Authorised / Registered Share Capital
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
09926
Description
Not applicable
Number of authorised/registered shares Balance at close of preceding month
Listed on the Exchange (Note 1)
Par value
5,000,000,000 USD
Increase / decrease (-) Balance at close of the month
Yes
Authorised/registered share capital 0.00001 USD
50,000
USD 5,000,000,000 USD Total authorised/registered share capital at the end of the month: USD
Page 1 of 10
0.00001 USD
50,000 50,000
v 1.2.1
FF301
II. Movements in Issued Shares and/or Treasury Shares and Public Float Sufficiency Confirmation
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
09926
Description
Not applicable
Number of issued shares (excluding treasury shares) Balance at close of preceding month
Number of treasury shares
Yes
Total number of issued shares
921,143,176
0
0
0
921,143,176
0
Increase / decrease (-) Balance at close of the month
Listed on the Exchange (Note 1)
921,143,176
921,143,176
Public float sufficiency confirmation (Note 4) Pursuant to Main Board Rule 13.32D(1) or 19A.28D(1) / GEM Rule 17.37D(1) or 25.21D(1), we hereby confirm that, in relation to the class of shares as set out above, as at the close of the month: ✔ the applicable public float requirement (see below) has been complied with the applicable public float requirement (see below) has not been complied with The applicable minimum public float requirement for the class of shares as set out above pursuant to Main Board Rule 13.32B or 19A.28B / GEM Rule 17.37B or 25.21B (as the case may be) is: Applicable public float threshold
Initial Prescribed Threshold - 25% of the total number of issued shares in the class to which the listed shares belong (excluding treasury shares)
Additional information
Page 2 of 10
v 1.2.1
FF301
III. Details of Movements in Issued Shares and/or Treasury Shares (A). Share Options (under Share Option Schemes of the Issuer)
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
09926
Description
Particulars of share option scheme
1).
Number of share options outstanding at close of preceding month
Post-IPO Share Option Scheme adopted on June 28, 2022 and amended on June 30, 2024
Not applicable
Number of share options outstanding at close of the month
Movement during the month
10,854,500 Granted
10,809,500
0
Exercised - new shares involved
0
Exercised - treasury shares involved
0
Cancelled
0
Lapsed
Listed on the Exchange (Note 1)
Yes
Number of treasury Number of new shares shares transferred out of issued during the month treasury during the pursuant thereto (A1) month pursuant thereto (A2)
0
The total number of Number of shares which shares which may be may be issued or issued or transferred out transferred out of of treasury upon treasury pursuant exercise of all share thereto as at close of options to be granted the month under the scheme at close of the month
0
1,066,000
71,131,017
-45,000
General Meeting approval date (if applicable)
Increase in issued shares (excluding treasury shares):
0
Ordinary shares (AA1)
Decrease in treasury shares:
0
Ordinary shares (AA2)
Total funds raised during the month from exercise of options: HKD
Page 3 of 10
0
v 1.2.1
FF301 (B). Warrants to Issue Shares of the Issuer
Not applicable
Page 4 of 10
v 1.2.1
FF301 (C). Convertibles (i.e. Convertible into Shares of the Issuer)
Not applicable
Page 5 of 10
v 1.2.1
FF301 (D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
09926
Description
Description of other agreements or arrangements
1).
Not applicable
General Meeting approval date (if applicable)
Listed on the Exchange (Note 1)
Number of treasury shares transferred Number of shares which may be issued out of treasury during the month or transferred out of treasury pursuant pursuant thereto (D2) thereto as at close of the month
Number of new shares issued during the month pursuant thereto (D1)
Post-IPO RSU Scheme adopted on December 6, 2021 and amended on June 30, 2024
Yes
0
0
Increase in issued shares (excluding treasury shares):
0
Ordinary shares (DD1)
Decrease in treasury shares:
0
Ordinary shares (DD2)
Page 6 of 10
0
v 1.2.1
FF301 (E). Other Movements in Issued Shares and/or Treasury Shares
Not applicable
Total increase/ decrease (-) in issued shares (excluding treasury shares) during the month (i.e. Total of AA1 to EE1):
0
Ordinary shares
Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2):
0
Ordinary shares
Page 7 of 10
v 1.2.1
FF301
IV. Information about Hong Kong Depositary Receipt (HDR)
Not applicable
Page 8 of 10
v 1.2.1
FF301
V. Confirmations
Not applicable
Submitted by:
XIA Yu
Title:
Director (Director, Secretary or other Duly Authorised Officer)
Page 9 of 10
v 1.2.1
FF301 Notes 1.
The Exchange refers to The Stock Exchange of Hong Kong Limited.
In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date". In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury".
The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number.
"Initial Prescribed Threshold”, "Alternative Threshold” and "market value" have the meanings ascribed thereto under Main Board Rule 13.32A or 19A.28A / GEM Rule 17.37A or 25.21A. See also Main Board Rule 13.32D(4) or 19A.28D(4) / GEM Rule 17.37D(4) or 25.21D(4) on the basis of the public float disclosure.
Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return.
“Identical” means in this context: .
the securities are of the same nominal value with the same amount called up or paid up;
.
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
.
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Page 10 of 10
v 1.2.1
2026-09-28
HONG KONG, Sep. 27, 2026 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy versus chemotherapy with or without nivolumab as first-line treatment for patients with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
The study is designed to further evaluate the efficacy and safety of cadonilimab as first-line therapy for advanced gastric cancer across geographically and ethnically diverse patient populations worldwide, and to investigate whether dual PD-1/CTLA-4 immune checkpoint blockade can further improve outcomes beyond the current standard of care.
COMPASSION-37 is co-led by a distinguished international group of global principal investigators, including Dr. Yelena Y. Janjigian, Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center (MSK); Professor Markus Möhler of Johannes Gutenberg University Mainz, Germany; Professor Jiafu Ji, Director of the Gastrointestinal Cancer Center at Peking University Cancer Hospital & Institute; and Professor Lin Shen, Director of the Department of Gastrointestinal Oncology at Peking University Cancer Hospital.
Dr. Janjigian, Professor Möhler, and Professor Shen were investigators on the CheckMate 649 trial, which established the clinical value of nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma and led to the adoption of PD-1 inhibitor plus chemotherapy as a key first-line treatment strategy for HER2-negative advanced gastric cancer.
As immunotherapy has become widely adopted in the first-line setting for gastric cancer, the relationship between PD-L1 expression and treatment benefit has drawn increasing attention. Studies including CheckMate 649 have shown that the benefit of PD-1 inhibitor plus chemotherapy is more pronounced in patients with high PD-L1 expression, while how to further improve immunotherapy outcomes in patients with low PD-L1 expression remains an important area of clinical investigation.
Chemotherapy with or without a PD-1 inhibitor remains the international standard of care for advanced gastric cancer; however, the disease is biologically and clinically heterogeneous. In the U.S., first-line PD-1 inhibitor indications in advanced gastric cancer are currently limited to PD-L1-positive patients, and current NCCN and ESMO guidelines preferentially recommend nivolumab-based regimens for patients with PD-L1 CPS ≥5. Consequently, effective immunotherapy options for PD-L1-low advanced gastric cancer remain a significant global unmet need.
"Immunotherapy has transformed the treatment of stomach and esophagus cancers, helping patients live longer and better," said Yelena Y. Janjigian, MD, FASCO, Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) and global principal investigator for the COMPASSION-37 study. "Through our evaluation of cadonilimab as a potential first-line treatment for advanced disease, we aim to better understand its potential to improve outcomes and support longer-term survival for patients." Dr. Janjigian previously served as the lead principal investigator for the CheckMate 649 trial, which established nivolumab-based therapy as a global standard of care.
Professor Jiafu Ji said: "COMPASSION-15 has already shown that cadonilimab plus chemotherapy significantly improves overall survival in patients with HER2-negative advanced gastric cancer, with a favorable survival trend also seen in patients with PD-L1 CPS <5, suggesting that dual PD-1/CTLA-4 blockade may expand the population that benefits from immunotherapy. COMPASSION-37 takes this further by evaluating the regimen in a global, multicenter, head-to-head Phase III trial against current international standards of care. Its greater value lies in rigorously testing the evidence we have generated on a worldwide scale. As clinicians, the key question is whether this innovation can offer more effective and broadly applicable first-line options for patients with advanced gastric cancer across different PD-L1 levels, regions, and populations. We look forward to COMPASSION-37 providing high-quality global evidence that can help bring clinically meaningful treatments to patients worldwide."
"Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the population that effectively benefits from immunotherapy is an important and not yet fully addressed clinical question in gastric cancer. We look forward to COMPASSION-37 further clarifying the value of dual PD-1/CTLA-4 immune checkpoint blockade across PD-L1 expression subgroups," said Professor Lin Shen.
From COMPASSION-15 to COMPASSION-37: From Chinese Phase III Evidence to Global Head-to-Head Validation
COMPASSION-15 is a randomized, double-blind, placebo-controlled Phase III study that enrolled 610 patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. The study enrolled a notably high proportion of patients with low PD-L1 expression (49.8%) and PD-L1-negative disease (23%), far exceeding rates in comparable historical studies. This provides strong support for the benefit of cadonilimab in the overall population, irrespective of PD-L1 expression.
Results from COMPASSION-15 study showed that, in the overall population, cadonilimab plus chemotherapy significantly reduced the risk of death compared with the control group, regardless of PD-L1 expression status. These findings suggest that dual PD-1/CTLA-4 immune checkpoint blockade may offer new therapeutic options for gastric cancer patients across different PD-L1 expression levels and provide an important scientific basis for further international head-to-head Phase III validation.
Gastric Cancer Immunotherapy: From "Whether" to "Who Benefits Most"
At present, PD-1 inhibitor plus chemotherapy has become one of the key first-line treatment strategies for HER2-negative advanced gastric cancer. However, multiple studies consistently suggest that the magnitude of immunotherapy benefit is closely associated with PD-L1 expression, with more definitive survival benefits in high-expressing patients and relatively modest absolute benefit in low-expressing patients.
PD-L1 expression thresholds and treatment recommendations vary across regions and guidelines. A single CPS cutoff should not be applied uniformly across all settings.This means that the central question in gastric cancer immunotherapy is gradually shifting from "whether immunotherapy should be added" to "how to select the most appropriate immunotherapy strategy based on tumor biology, and how to further broaden the population that truly derives long-term benefit." COMPASSION-37 is being conducted against this backdrop.
Advancing Global Clinical Development
In addition to COMPASSION-37, an international study of cadonilimab in the perioperative setting for gastric cancer has also been initiated. A single-arm Phase II study (NCT07631000), led by Dr. Yelena Y. Janjigian at Memorial Sloan Kettering Cancer Center, is currently enrolling patients in the United States. The study evaluates cadonilimab in combination with FLOT chemotherapy as perioperative treatment in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma, exploring whether dual PD-1/CTLA-4 immune checkpoint blockade can be extended to earlier-stage, curable gastric cancer.
From the randomized Phase III COMPASSION-15 study conducted in China, to the perioperative Phase II study being conducted in the United States, and now to the global, multicenter, head-to-head Phase III COMPASSION-37 study, the clinical development of cadonilimab in gastric cancer is progressively forming a complete pathway that spans from advanced disease to the perioperative setting and from Chinese evidence to global validation.
Whether COMPASSION-37 can further improve patient survival beyond the current standard of care—and, in particular, whether it can offer a new treatment option for patients with low PD-L1 expression—will ultimately be answered by the results of this rigorous Phase III trial. This is the key scientific question that COMPASSION-37 is designed to answer.
In addition to the COMPASSION-37 study, a Phase II study (NCT07631000) of perioperative cadonilimab with neoadjuvant chemotherapy in patients with localized, resectable HER2-negative gastric or gastroesophageal junction (GEJ) tumors, led by Dr. Yelena Janjigian, is currently enrolling patients in the United States. This study is expected to generate robust clinical evidence to support the initiation of an international multicenter Phase III trial evaluating the cadonilimab-based combination regimen for the perioperative treatment of patients with GC/GEJ adenocarcinoma.
As the first approved bispecific antibody for cancer treatment, cadonilimab continues to demonstrate clinical value across multiple pivotal registrational and Phase III studies. It is currently approved in China for first-line gastric cancer, first-line cervical cancer, and recurrent/metastatic cervical cancer, and is widely used in clinical practice. Cadonilimab is being evaluated in more than 13 registrational or Phase III trials globally, spanning major tumor types including gastric, liver, lung, cervical, and pancreatic cancers. Two of these trials are international multicenter registrational/Phase III studies.
About cadonilimab
Cadonilimab is a first-in-class PD-1/CTLA-4 bispecific antibody developed by Akeso for cancer immunotherapy. In June 2022, it received initial marketing approval from China's National Medical Products Administration (NMPA) for the treatment of patients with relapsed or metastatic cervical cancer who had progressed on or after platinum-based chemotherapy. In September 2024, cadonilimab was approved in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. In May 2025, cadonilimab plus platinum-based chemotherapy, with or without bevacizumab, was approved for the first-line treatment of persistent, recurrent, or metastatic cervical cancer.
By simultaneously targeting PD-1 and CTLA-4, cadonilimab delivers synergistic antitumor activity. It has shown robust efficacy with markedly lower toxicity and improved tolerability compared with conventional combination regimens, demonstrating potent activity across multiple tumor types independent of PD-L1 expression and offering breakthrough clinical value in immunotherapy-resistant and "cold" tumors.
To date, cadonilimab has been evaluated in more than 40 clinical studies spanning over 20 indications, including gastric, lung, liver, cervical, and pancreatic cancers. Thirteen Phase III/registrational studies are ongoing, three have met their primary endpoints, and two global Phase III/registrational trials are advancing.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.
Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
2026-09-22
HONG KONG, Sept. 21, 2026 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23–27 in Madrid, Spain. The presentations include one Late-Breaking Abstract (LBA) selected for the Presidential Symposium and two oral presentations.
Ivonescimab, the world's first approved PD-1/VEGF bispecific antibody, will be featured in 12 presentations at ESMO 2026. Notably, positive overall survival results from the Phase III HARMONi-GI1 trial evaluating ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer have been selected as a Late-Breaking Abstract for the Presidential Symposium and will be delivered as a late-breaking oral presentation. In addition, two rapid oral presentations will present breakthrough data on ivonescimab-based regimens as first-line treatment for advanced renal cell carcinoma and recurrent/metastatic thymic carcinoma. The presentations will also highlight ivonescimab's expanding development across multiple tumor types, including continued progress in lung cancer (including brain metastases), gastrointestinal cancers (esophageal and gastric cancer), and rare or difficult-to-treat malignancies such as pancreatic cancer, glioblastoma, endometrial cancer, thymic carcinoma, and head and neck squamous cell carcinoma.
Cadonilimab, the world's first PD-1/CTLA-4 bispecific antibody, will be featured in 15 presentations covering more than ten tumor types, including gastric cancer, renal cell carcinoma, lung cancer, esophageal squamous cell carcinoma, colorectal cancer, nasopharyngeal carcinoma, ovarian cancer, soft tissue sarcoma, pleural mesothelioma, and rectal cancer. These studies span neoadjuvant settings as well as first- and second-line treatment of advanced disease, underscoring the broad anti-tumor potential of this dual checkpoint inhibitor.
The extensive data to be presented at ESMO 2026 reflect Akeso's ongoing commitment to advancing next-generation immuno-oncology therapies for major global diseases and our continued efforts to build a differentiated global oncology portfolio. Full results will be released during the Congress. Please stay tuned for updates.
Key Presentations Highlights:
LBA8 - Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double- blinded, Phase 3 trial (HARMONi-GI1)
-
Speakers: Jian Zhou (Shanghai, China)
-
Session Name: Presidential Symposium II
-
Room: Alicante Auditorium - Hall 6
-
Date: Sunday, 25 October 2026
-
Time: 16:30 - 18:15 (Madrid)
Efficacy and Safety of AK112 (Ivonescimab), a PD-1/VEGF Bispecific Antibody, as First-Line Treatment for Patients with IMDC Favorable-Risk Advanced Renal Cell Carcinoma (aRCC): Results from a Phase Ib/II Study
-
Session: Rapid Oral 2: Genitourinary tumours, renal and urothelial
-
Abstract: 3592RO
-
Presentation time: Sunday, 25 October 2026, 14:45–16:15 (Madrid)
-
Presenter: Professor Xieqiao Yan, Peking University Cancer Hospital
Ivonescimab plus chemotherapy as first-line treatment in recurrent/metastatic thymic carcinoma: interim results from the iTHYM study
-
Session: Rapid Oral: Non-metastatic NSCLC and other thoracic malignancies
-
Abstract: 4156RO
-
Presentation time: Monday, 26 October 2026, 10:15–11:45 (Madrid)
-
Presenter: Professor Xue Hou, Sun Yat-sen University Cancer Center
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.
Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
2026-09-03
Hong Kong, September 3, 2026 — Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Data Monitoring Committee (IDMC), met the key secondary endpoint of OS. The results demonstrated that ivonescimab showed statistically significant and clinically meaningful improvement over pembrolizumab.
HARMONi-2 is a randomized, double-blind, multicenter, registrational Phase III trial evaluating ivonescimab, Akeso’s first-in-class PD-1/VEGF bispecific antibody, versus pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (TPS ≥1%).
Detailed data from the interim OS analysis will be presented at an upcoming international medical conference and published in a peer-reviewed journal.
In May 2024, at a prespecified interim analysis conducted by the IDMC, ivonescimab met its primary endpoint of progression-free survival (PFS) in the HARMONi-2 study, with a median PFS of 11.14 months versus 5.82 months for pembrolizumab. HARMONi-2 is the first randomized, double-blind Phase III trial to show a significant positive outcome against pembrolizumab in this setting.
In 2025, this indication received regulatory approval in China. The approval removed previous restrictions on the use of VEGF-targeted agents in patients with squamous histology and provided a chemotherapy-free treatment option that has been well received in clinical practice.
Currently, the international multicenter Phase III study of ivonescimab monotherapy versus pembrolizumab as first-line treatment for PD‑L1 high‑expressing NSCLC (HARMONi-7/ AK112-3007) is ongoing.
Dr. Yu Xia, Founder, Chairwoman, President and Chief Executive Officer of Akeso:
“We are pleased that the fourth Phase III study of an ivonescimab-based regimen has now demonstrated statistically significant benefit in both overall survival and progression-free survival. These results further reinforce the clinical value of ivonescimab in the treatment of lung cancer.
We thank the investigators, clinical teams and patients who participated in the HARMONi-2 study for their important contributions.
To date, ivonescimab has achieved dual positive OS and PFS outcomes across multiple Phase III head-to-head trials versus PD-1/PD-L1 therapies. This growing body of evidence strengthens our confidence in its potential across a broader range of solid tumors. With its unique dual mechanism of action combining immunotherapy and anti-angiogenesis, we believe ivonescimab offers a more effective treatment option for patients and will contribute meaningfully to the evolving oncology treatment landscape.”
2026-08-28
HONG KONG, Aug. 27, 2026-- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively built its IO2.0 + ADC2.0 therapeutic matrix, and continued orderly development of bispecific antibodies in major chronic disease areas, including autoimmune, respiratory, and central nervous system (CNS) disorders
Commercialization Reaches Record High
Commercial sales revenue for the first half of 2026 reached approximately RMB 1,803.2 million, representing a 28.7% increase year-over-year. As of the reporting date, the Company's total cash and cash equivalents, together with other short-term financial assets, stood at RMB 9,160.0 million.
By the end of 2025, all 12 indications across the Company's five self-commercialized innovative drugs had been included in China's National Reimbursement Drug List (NRDL). These include two non-small cell lung cancer (NSCLC) indications for ivonescimab (PD-1/VEGF bispecific antibody) and three cervical and gastric cancer indications for cadonilimab (PD-1/CTLA-4 bispecific antibody). NRDL inclusion has significantly expanded market coverage and patient access.
In August 2026, the National Medical Products Administration (NMPA) approved ivonescimab in combination with chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC), providing a new growth driver for commercialization.
Since the beginning of 2026, the Company has continued to strengthen its commercialization capabilities, with steady progress in market access, coverage, and penetration. These efforts lay a solid foundation for the sustained release of innovative drug value in the second half of the year and beyond.
IO2.0 Global Strategy Advances
Following the approvals of ivonescimab and cadonilimab - two first-in-class immuno-oncology (IO) cornerstone therapies - Akeso has continued to advance the Company's global IO2.0+ strategy. The Company is building a bispecific antibody-based IO therapeutic matrix designed to treat multiple tumor types through combining different types of therapy.
Biliary tract cancer: In August 2026, the Phase III clinical study of ivonescimab plus chemotherapy versus durvalumab plus chemotherapy for the first-line treatment of advanced biliary tract cancer met its primary endpoint of overall survival (OS), demonstrating clinically meaningful and statistically significant OS benefit. This regimen represents a major advancement in first-line treatment of biliary tract cancer.
Squamous NSCLC: In August 2026, ivonescimab plus chemotherapy received NMPA approval for first-line treatment of sq-NSCLC. Based on the HARMONi-6 study, this is the first regimen to achieve dual positive OS and progression-free survival (PFS) results versus a PD-1 monoclonal antibody plus chemotherapy in a randomized, double-blind Phase III trial. Ivonescimab combination therapy marks a significant advance in first-line sq-NSCLC treatment.
EGFR-TKI-resistant NSCLC: In July 2026, an updated analysis of the global multicenter Phase III HARMONi study demonstrated continued OS improvement (HR = 0.76). The OS hazard ratio in Western patients was also 0.76, highly consistent with the China-conducted HARMONi-A study (HR = 0.74, P = 0.02). The Biologics License Application (BLA) for this indication is currently under review by the U.S. Food and Drug Administration (FDA). The HARMONi-A study is the first immuno-oncology trial globally to achieve dual positive OS and PFS results with both clinical benefit and statistical significance in this setting. Ivonescimab combination therapy represents a major advancement in the treatment of EGFR-TKI-resistant non-squamous NSCLC.
PD-L1-positive NSCLC: In the HARMONi-2 study, ivonescimab became the first therapy globally to demonstrate positive results versus pembrolizumab in a Phase III trial, establishing a new benchmark in first-line treatment of PD-L1-positive NSCLC.
Cadonilimab: Cadonilimab continues to advance across multiple indications, including gastric cancer and hepatocellular carcinoma (HCC). Key programs include an international multicenter Phase III study of cadonilimab plus chemotherapy versus nivolumab plus chemotherapy for first-line treatment of gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, a perioperative Phase II study in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC), and an international multicenter registrational study of cadonilimab plus lenvatinib in HCC patients who progressed after prior atezolizumab plus bevacizumab.
As cornerstone agents of global IO2.0, ivonescimab and cadonilimab are establishing a combination therapy ecosystem through novel mechanisms, with the potential to elevate the standard of care across multiple tumor types. Ivonescimab is currently being evaluated in combination trials with Revolution Medicines' RAS(ON) inhibitor, ARCUS Biosciences' HIF-2α inhibitor, Virogin Biotech's VG201 oncolytic virus, and TransThera Biosciences' tinengotinib, spanning NSCLC, pancreatic cancer, colorectal cancer, clear cell renal cell carcinoma, and hepatocellular carcinoma. Cadonilimab is advancing multi-pathway combination strategies, including combinations with small molecules such as axitinib and tinengotinib in renal and liver cancers, as well as collaborations with the Dana-Farber Cancer Institute and Mass General Brigham to evaluate cadonilimab in combination with INOVIO's DNA medicine INO-5412 in glioblastoma (GBM).
Ivonescimab is currently being evaluated in more than 17 registrational Phase II/III studies, including seven global registrational trials and 8 studies that use standard-of-care regimens as active comparators. These programs encompass 8 registrational/Phase III studies in lung cancer, as well as first-line MSS/pMMR colorectal cancer, first-line PD-L1-positive head and neck squamous cell carcinoma (in combination with CD47 antibody versus pembrolizumab), first-line biliary tract cancer (versus a durvalumab-based regimen), first-line triple-negative breast cancer, first-line pancreatic cancer, and first-line urothelial cancer (versus pembrolizumab plus a Nectin-4 ADC).
Cadonilimab is being evaluated in more than 13 registrational/Phase III clinical studies covering major cancer types, including gastric cancer, HCC, lung cancer, cervical cancer, pancreatic cancer, and esophageal squamous cell carcinoma. Two of these are international multicenter registrational studies.
IO2.0 + ADC2.0 Therapeutic Matrix
Akeso is the only company globally with two approved immuno-oncology bispecific antibodies and is actively exploring combination therapies of ivonescimab and cadonilimab with both proprietary and partnered antibody-drug conjugates (ADCs).
The Company has developed a series of next-generation ADCs designed to address the narrow therapeutic window associated with the safety limitations of existing ADC therapies. Among these, the innovative TROP2/Nectin-4 bispecific ADC AK146D1, next-generation HER3 ADC AK138D1, next-generation B7H3 ADC AK157D1, and bispecific ADC AK158D1 have successively entered clinical development.
Multiple Phase II studies evaluating AK146D1 in combination with ivonescimab in NSCLC, breast cancer, and urothelial cancer, as well as AK138D1 in combination with ivonescimab in lung and breast cancers, are underway, with a focus on first-line treatment of various solid tumors.
In parallel, ivonescimab has entered combination therapy collaborations with high-potential ADCs from domestic and international partners, including Pfizer, GSK, Biokin, and MediLink. These collaborations cover agents such as EGFR/HER3 bispecific ADC, TROP2/HER3 bispecific ADC, B7H3 ADC, FGFR2b ADC, TROP2 ADC, and Nectin-4 ADC across high-incidence malignancies.
Looking further ahead, the Company's frontier programs continue to push additional new therapies into the clinic. The global first-in-class trispecific antibody AK150 (ILT2/ILT4/CSF1R) has entered clinical development, with additional trispecific antibodies and T-cell engager (TCE) bispecific/multispecific candidates expected to enter the clinic in the next year.
Entering the Bispecific Era in Immunology, CNS, and Respiratory Diseases
In autoimmune, respiratory, and CNS diseases, Akeso is leveraging its expertise in bispecific and multispecific antibody development, with strategic momentum steadily building. A series of internally-developed novel candidates, including AK139, a bispecific antibody for Immunology & Inflammation that targets IL-4R and ST2, and AK152, a bispecific amyloid-beta + brain shuttle antibody for the treatment of Alzheimer's disease have entered or are preparing to enter clinical development. These programs form a complementary pipeline alongside the Company's already marketed non-oncology products: ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), gumokimab (IL-17), and manfidokimab (IL-4Rα).
AI-Empowered Future Innovation Competitiveness
Akeso has adopted the use of AI in its R&D efforts for the past few years. The Company is further expanding the implementation of AI in many new scientific directions and therapeutic platforms.
Developed on Akeso's AI-driven drug discovery platform, AK139, an IL-4Rα/ST2 bispecific antibody, has advanced into 7 Phase II trials across respiratory and autoimmune indications. AK150, an ILT2/ILT4/CSF1R trispecific antibody, is in Phase I development. AK154, a personalized mRNA cancer vaccine that leverages AI-powered selection of high-affinity immunogenic mutations to create precision oncology therapies. A Phase I study of AK154 as monotherapy or in combination with cadonilimab or ivonescimab as adjuvant therapy in pancreatic cancer is currently ongoing.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multispecific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.
Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
The Board hereby announces the unaudited condensed consolidated interim results of the Group for the six months ended June 30, 2026. In this announcement, “we,” “us” and “our” refer to the Company or where the context requires otherwise, the Group. FINANCIAL HIGHLIGHTS 1.
Revenue The Group’s revenue increased by 27.92% from RMB1,411.5 million in the first half of 2025 (for the six months ended June 30, 2025) to RMB1,805.7 million in the first half of 2026 (for the six months ended June 30, 2026). The Group’s revenue consists of commercial sales and license income. The Group’s total commercial sales, net of distribution cost increased by 28.65% from RMB1,401.6 million in the first half of 2025 to RMB1,803.2 million in the first half of 2026. License income in the first half of 2026 was RMB2.5 million.
–1–
Gross Profit The Group’s gross profit was RMB1,120.7 million in the first half of 2025 and RMB1,340.5 million in the first half of 2026.
Profit/Loss for the Period The Group recorded a loss of RMB447.2 million in the first half of 2026, as compared to a loss of RMB588.3 million in the first half of 2025. The loss decreased by RMB141.1 million compared to the same period last year. The reduction in this loss is mainly attributable to: 1)
During the Reporting Period, the proportion of the Group’s selling and marketing expenses to commercial sales revenue decreased by 4.24% year-on-year owing to the continuous growth in commercial sales revenue and continuous improvement in commercial operational efficiency. In the first half of 2026, selling and marketing expenses accounted for 43.56% of commercial sales revenue, compared to 47.80% in the first half of 2025.
In accordance with IFRS, the Group accrued equity investment losses on Summit Therapeutics (NASDAQ: SMMT) based on the loss amount and shareholding ratio of Summit Therapeutics (NASDAQ: SMMT) during the Reporting Period, which decreased by 40.45% year-over-year. In the first half of 2026, the accrued amount for this investment loss was RMB114.2 million. The provision for this investment loss in the first half of 2025 was RMB191.7 million, and the provision for this investment loss decreased by RMB77.5 million.
–2–
MANAGEMENT DISCUSSION AND ANALYSIS Akeso, Inc., established in 2012, adheres to its original aspiration of “developing globally leading innovative drugs in China, enabling patients to be among the first to benefit from the world’s most advanced treatment regimens.” Leveraging its advanced bispecific/multispecific antibody technologies, the Company has successfully developed and launched the world’s first-in-class bispecific drugs — cadonilimab (PD-1/CTLA4) and ivonescimab (PD-1/VEGF) — making it the only pharmaceutical company worldwide with two immuno oncology (IO) bispecific antibodies. This has ushered in the IO 2.0 era of global tumor immunotherapy and spearheaded the international wave of bispecific antibody development, establishing the Company as a globally influential innovative enterprise. Currently, the Company has built a proprietary end-to-end drug R&D platform, empowering the entire drug development process with AI. Building on its strength in bispecific/multispecific antibody technologies, it has expanded its R&D landscape into cutting-edge modalities such as ADC/bispecific-ADC, TCE, siRNA, cell therapy, and mRNA. The Company has developed over 50 innovative drug candidates for major diseases including cancer, autoimmune diseases, respiratory diseases, central nervous system disorders, inflammatory conditions, and metabolic diseases. Nearly 30 novel drugs are currently in clinical development (including 15 bispecific/multispecific antibodies/bispecific-ADCs), with 12 products in Phase III clinical trials and 17 products in Phase I/II clinical trials. 8 novel drugs have been launched, and 12 approved indications of the Company’s first five proprietary commercialized novel drugs have been included in the latest version of the NRDL.
The commercialization rights for this product were granted to JumpCan Pharmaceutical in February 2026.
–3–
During the Reporting Period, the Company recorded revenue of approximately RMB1,805.7 million, representing an increase of 27.92% compared to approximately RMB1,411.5 million in the corresponding period last year. Among which, commercial sales revenue amounted to approximately RMB1,803.2 million, an increase of 28.65% from approximately RMB1,401.6 million in the corresponding period last year. The increase was primarily attributable to the significant sales contribution from Akeso’s bispecific antibodies, 開坦尼® (cadonilimab, PD-1/CTLA-4) and 依達方® (ivonescimab, PD-1/VEGF). Several other commercialized products of the Company have also contributed in part to the sales growth, including 伊喜寧® (ebronucimab, PCSK9) and 愛 達羅® (ebdarokimab, IL-12/IL-23). 12 approved indications of the Company’s first five proprietary commercialized novel drugs have been included in the latest version of the NRDL, with hospital access achieving broad coverage and deep penetration. As of June 30, 2026, the Company has established a specialized and systematic sales team of over 1,600 people, comprehensively covering the two core areas of oncology and specialty drugs. The Company actively promotes a “patient-centric” “academic marketing” approach, extensively explores diversified channels such as commercial health insurance, driving sustainable growth for the existing product portfolio and maximizing synergistic advantages. In addition, the Company also received license income from two product partners during the Reporting Period, totaling approximately RMB2.5 million. ONCOLOGY 依達方® (ivonescimab, PD-1/VEGF) Ivonescimab has become the most valuable therapy in the current global R&D pipeline. In the latest “World Preview 2026” report published by Evaluate Pharma, ivonescimab ranked first globally in terms of total pipeline value, with a risk-adjusted net present value (NPV) exceeding USD25.2 billion. The Company has initiated over 60 clinical trials through combination therapies for ivonescimab, including over 40 indications, 17 registrational Phase II/III clinical trials and 8 head-to-head studies with PD-(L)1, 5 of which have achieved positive results, covering lung cancer, colorectal cancer, biliary tract cancer, head and neck squamous cell carcinoma (HNSCC), breast cancer, pancreatic cancer, urothelial carcinoma and other tumor types. Furthermore, ivonescimab has been included in 12 authoritative clinical treatment guidelines and expert consensus in China.
–4–
Ivonescimab currently has three approved indications in China, with the first two included in the latest version of the NRDL. These include: •
For the treatment of EGFR-mutated, locally advanced or metastatic non-squamous NSCLC progressed after EGFR-TKI therapy;
•
For the first-line treatment of PD-L1 positive (TPS≥1%) locally advanced or metastatic NSCLC; and
•
For the first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC).
Furthermore, the application of Biologics License Application (BLA) is under review by FDA: •
For the treatment of EGFR-mutated NSCLC progressed after third-generation EGFR-TKI therapy.
As the global leader in the PD-1/VEGF therapeutic class, the efficacy, safety, longterm survival benefits of ivonescimab have been consistently and thoroughly validated through multiple Phase III clinical studies across China, North America and Europe. Ivonescimab is reshaping the treatment landscape for lung cancer and several major tumor types, including cold tumors. These clinical advancements will unlock ivonescimab’s transformational therapeutic value. Comprehensive coverage of core lung cancer indications, solidifying first-mover advantage and long-term survival benefits Ivonescimab has achieved full-spectrum coverage of lung cancer indications and is reshaping the global lung cancer treatment paradigm. •
In August 2026, ivonescimab in combination with chemotherapy for first-line treatment of sq-NSCLC received NMPA approval for marketing, marking the third indication for ivonescimab to be approved in China. This approval fills the clinical gap resulting from the contraindication of anti-angiogenic agents in sq-NSCLC, and offers patients a novel treatment option leveraging the synergistic anti-tumor effect of immunotherapy combined with anti-angiogenesis. The approval was based on the Phase III study HARMONi-6/AK112-306, whose significant positive overall survival (OS) results were presented at the 2026 ASCO Plenary Session and simultaneously published in THE LANCET. This is the first global Phase III study to demonstrate statistically significant PFS and OS benefits versus PD-1 plus chemotherapy in lung cancer. The results showed that the ivonescimab combination significantly reduced the risk of death and disease progression.
–5–
•
Patient enrollment is ongoing in the Phase III clinical study (HARMONi-8A/ AK112-305) of ivonescimab in combination with docetaxel versus docetaxel in patients with locally advanced or metastatic NSCLC who have progressed after prior PD-(L)1 inhibitor and platinum-based chemotherapy. As the first immune bispecific antibody currently in a Phase III clinical study for IO-resistant NSCLC, ivonescimab is poised to potentially address this significant unmet clinical need.
•
In Small Cell Lung Cancer (SCLC), the Phase III clinical study (HARMONi-9/ AK112-311) of ivonescimab as consolidation therapy in patients with limitedstage SCLC who have not progressed after standard concurrent chemoradiotherapy is also enrolling patients. In June 2026, results of the Phase II clinical study of ivonescimab in combination with chemotherapy as second-line treatment for SCLC were presented as an oral presentation at 2026 ASCO.
•
In June 2026, the significantly positive OS final analysis results of the Phase III clinical study (HARMONi-A/AK112-301) of ivonescimab in combination with chemotherapy for NSCLC progressing after EGFR-TKI therapy were published in JAMA, marking the first immunotherapy Phase III study to achieve clinically meaningful and statistically significant benefits in both core endpoints of PFS and OS.
Efficient advancement of five Phase III indications, expanding into “Cold Tumors” Multiple clinical studies are currently ongoing, covering five indications in colorectal cancer, pancreatic cancer, biliary tract cancer, HNSCC, and triple-negative breast cancer. •
In August 2026, the Phase III clinical study (HARMONi-GI1/AK112-309) of ivonescimab in combination with chemotherapy versus durvalumab in combination with chemotherapy for the first-line treatment of advanced biliary tract cancer met primary endpoint of OS, demonstrating statistically significant and clinically meaningful benefits. In February 2026, this regimen was granted Breakthrough Therapy Designation by the NMPA. In June 2026, data from the Phase Ib/II study (AK130-201) of ivonescimab in combination with AK130 (TIGIT/TGF-β) for previously treated advanced biliary tract cancer were presented at 2026 ASCO.
•
Patient enrollment is ongoing in the Phase III clinical study (HARMONi-GI6/ AK112-312) of ivonescimab in combination with chemotherapy versus bevacizumab in combination with chemotherapy for the first-line treatment of metastatic colorectal cancer. In June 2026, interim analysis data from the international multicenter Phase II clinical study of ivonescimab in combination with chemotherapy for the first-line treatment of metastatic colorectal cancer were presented at 2026 ASCO, further validating the consistency of ivonescimab’s global data.
–6–
•
Patient enrollment is ongoing in the Phase III clinical study (HARMONi-BC1/ AK112-308) of ivonescimab in combination with chemotherapy versus chemotherapy for the first-line treatment of locally advanced unresectable or metastatic triplenegative breast cancer (TNBC) with negative PD-L1 expression. In November 2025, this regimen was granted Breakthrough Therapy Designation by the NMPA.
•
Patient enrollment is ongoing in the Phase III clinical study (HARMONi-GI2/ AK112-310) of ivonescimab in combination with chemotherapy with or without ligufalimab (AK117, CD47) versus chemotherapy for the first-line treatment of metastatic pancreatic cancer.
•
Patient enrollment is ongoing in the Phase III clinical study (HARMONi-HN1/ AK117-302) of ivonescimab in combination with ligufalimab versus pembrolizumab for the first-line treatment of recurrent or metastatic PD-L1 positive HNSCC. In June 2026, results of an exploratory Phase II clinical study of ivonescimab in combination with chemotherapy as neoadjuvant therapy for resectable locally advanced HNSCC were presented as an oral presentation at 2026 ASCO.
First overseas BLA submitted and accepted; updated data further validate consistency In overseas, our partner SUMMIT submitted a BLA to the FDA for ivonescimab in combination with chemotherapy for NSCLC progressing after third-generation EGFRTKI therapy, which was formally accepted in January 2026 and is currently under review. This marks the first indication application for ivonescimab overseas and a significant milestone for a self-developed Chinese bispecific antibody drug entering the global market. The latest OS analysis for the global multi-regional Phase III study (HARMONi) conducted in June 2026 showed that OS improved in both the ITT and Western populations, highly consistent with the results of the Chinese Phase III HARMONi-A study, further reinforcing that ivonescimab demonstrates consistent efficacy and safety across global regions and populations.
–7–
Several global registrational Phase II/III trials for first-line large indications •
The global multi-regional Phase III clinical study (HARMONi-3) of ivonescimab in combination with chemotherapy versus pembrolizumab in combination with chemotherapy for first-line treatment of NSCLC comprises two independent cohorts, squamous and non-squamous, with independent statistical analysis. The squamous cohort completed enrollment in February 2026, and the non-squamous cohort completed enrollment in June 2026.
•
The global multi-regional Phase III clinical study (HARMONi-7) of ivonescimab versus pembrolizumab for first-line treatment of NSCLC with high PD-L1 expression (TPS≥50%) is ongoing.
•
The global multi-regional Phase III clinical study (HARMONi-GI3) of ivonescimab in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer is ongoing.
•
The international multi-center Phase III clinical study (ILLUMINE) of ivonescimab with or without ligufalimab versus pembrolizumab for first-line treatment of PDL1 positive HNSCC, sponsored by GORTEC (Head and Neck Radiotherapy Study Group) and supported by SUMMIT and the Company, is ongoing.
•
In August 2026, the international multi-center registrational Phase II/III clinical study (HARMONi-GU1) in combination with enfortumab vedotin (EV, Nectin-4 ADC) versus pembrolizumab plus EV for first-line treatment for locally advanced or metastatic urothelial carcinoma was initiated.
Preferred IO 2.0 backbone therapy, strong alliances with multiple global innovative mechanisms As a cornerstone immuno-oncology (IO) 2.0 drug, ivonescimab is combined with therapies across multiple platforms, including bispecific antibodies, monoclonal antibodies, ADC, and mRNA cancer vaccines. Through both the Company’s internal research programs and external collaborations, these combinations aim to create novel therapeutic combinations across lung cancer, gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, HNSCC, and biliary tract cancer. Ivonescimab is involved in over 20 combination clinical studies.
–8–
Ivonescimab’s overseas combination landscape is expanding as well. •
SUMMIT is collaborating with Revolution Medicines, Inc. (NASDAQ: RVMD) to evaluate the safety and efficacy of ivonescimab combined with three RAS(ON) inhibitors in multiple solid tumors.
•
In January 2026, SUMMIT announced a collaboration with GSK Plc (NYSE: GSK) to evaluate ivonescimab in combination with GSK’s B7H3 ADC in multiple solid tumors, with a focus on refractory cancers, such as SCLC.
•
In July 2026, SUMMIT announced a collaboration with Arcus Biosciences, Inc. (NYSE: RCUS) to advance an international multi-center clinical study of ivonescimab in combination with Arcus’s HIF-2α inhibitor, casdatifan, for the treatment of clear cell renal cell carcinoma.
•
In August 2026, the international multi-center registrational Phase II/III clinical study (HARMONi-GU1) of ivonescimab in combination with enfortumab vedotin (EV, Nectin-4 ADC) versus pembrolizumab plus EV for first-line treatment for locally advanced or metastatic urothelial carcinoma was initiated.
Ivonescimab is widely favored by global partners as the preferred choice for combination or breakthrough therapy exploration across various tumor types. These collaborations will further expand the global clinical development and adoption of ivonescimab, solidifying its position as the backbone therapy in IO 2.0. 開坦尼® (cadonilimab, PD-1/CTLA-4) Cadonilimab is currently approved or in clinical studies for over 20 indications. These includes cervical cancer, gastric cancer, lung cancer, liver cancer, kidney cancer, and brain cancer. Over 40 clinical trials have been initiated in China and overseas, with approximately 13 registrational Phase II/III clinical trials actively progressing. It continues to be included in over 20 authoritative clinical treatment guidelines. Currently, cadonilimab has three approved indications in China, all of which have been included in the latest version of the NRDL, including: •
For the treatment of recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy;
•
For the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma; and
•
For the first-line treatment of persistent, recurrent, or metastatic cervical cancer.
–9–
The Company is also expanding the global development strategy for cadonilimab, committed to accelerating Chinese therapeutic innovation to treat critical global medical needs. Gastric cancer: comprehensive coverage across first-line, IO resistance and perioperative settings Cadonilimab is currently the only immunotherapy agent for first-line treatment of gastric cancer that benefits the entire patient population, addressing the efficacy gap of PD-(L)1 products in patients with low or negative PD-L1 expression. Two Phase III clinical trials in the gastric cancer field in China are also enrolling patients: •
The Phase III clinical study (COMPLUS-5) of cadonilimab in combination with pulocimab (AK109, VEGFR2) and chemotherapy for the treatment of IO-resistant G/GEJ adenocarcinoma; and
•
The Phase III clinical study (COMPASSION-33) of cadonilimab in combination with chemotherapy for perioperative treatment of G/GEJ adenocarcinoma.
Advancing globally, gastric cancer global clinical studies ongoing •
In June 2026, the global multi-regional Phase III clinical study (AK104-311/ COMPASSION-37) of cadonilimab in combination with chemotherapy versus chemotherapy with or without nivolumab for the first-line treatment of HER2negative, unresectable or metastatic G/GEJ adenocarcinoma was fully initiated.
•
In July 2026, the Company, together with Memorial Sloan Kettering Cancer Center, is advancing a Phase II clinical study of cadonilimab in combination with chemotherapy for perioperative treatment of locally advanced, resectable GEJ adenocarcinoma, with patient enrollment ongoing in the U.S.
– 10 –
Differentiated lung cancer clinical study layout, exploring broader clinical needs via combination therapies •
Patient enrollment is ongoing in the Phase II/III clinical study (COMPASSION-28) of cadonilimab in combination with chemotherapy versus tislelizumab in combination with chemotherapy as first-line treatment for PD-L1 negative locally advanced or metastatic NSCLC.
•
Patient enrollment is ongoing in the Phase II/III clinical study (COMPASSION-30) of cadonilimab versus sugemalimab for unresectable locally advanced NSCLC with disease progression after concurrent/sequential chemoradiotherapy.
Liver cancer: clinical study in China on track, global multi-regional registrational Phase II clinical study initiated •
Patient enrollment was completed in March 2025 for the Phase III clinical study (COMPASSION-22) of cadonilimab monotherapy as adjuvant therapy for postoperative hepatocellular carcinoma.
•
Patient enrollment is ongoing in the Phase II/III clinical study (COMPASSION-29) of cadonilimab in combination with lenvatinib plus transcatheter arterial chemoembolization (TACE) for intermediate to advanced unresectable hepatocellular carcinoma (uHCC).
•
The global multi-regional registrational Phase II clinical study (COMPASSION-36) of cadonilimab in combination with lenvatinib for the treatment of IO-resistant hepatocellular carcinoma was officially initiated in August 2025, with patient enrollment ongoing.
New entry into two gastrointestinal cancers, indications continuously expanding •
The Phase III clinical study (COMPASSION-40) of cadonilimab monotherapy as neoadjuvant/adjuvant therapy for resectable MSI-H/dMMR colon cancer was officially initiated in the first half of 2026, with patient enrollment ongoing.
•
The Phase II/III clinical study (COMPASSION-38) of cadonilimab in combination with chemotherapy for perioperative treatment of resectable esophageal squamous cell carcinoma was initiated in the first half of 2026.
– 11 –
Long-term survival benefits, comprehensively reshaping the treatment landscape of cervical cancer •
In March 2026, the latest long-term survival analysis data from the pivotal Phase II registrational study (COMPASSION-03/AK104-201) of cadonilimab monotherapy for recurrent/metastatic cervical cancer were presented at 2026 ESGO, confirming that cadonilimab translates deep tumor responses into durable disease control and long-term survival benefits. In March 2026, a Phase III investigator-initiated trial (IIT) of cadonilimab in combination with chemotherapy followed by sequential concurrent chemoradiotherapy for locally advanced cervical cancer was initiated. This study aims to fully leverage the established advantages of cadonilimab in cervical cancer and address the unmet clinical needs in this patient population.
Continuous exploration of additional tumor types, fully unlocking product potential •
In April 2026, results of the Phase II clinical study (COMPASSION-26) of cadonilimab in combination with chemotherapy for the first-line treatment of advanced pancreatic cancer (PDAC) were presented at 2026 AACR. The cadonilimab combination demonstrated promising anti-tumor activity and survival benefits, offering a new treatment hope.
•
In April 2026, results of the Phase II study (CARE) of cadonilimab in combination with chemotherapy for the first-line treatment of advanced or recurrent endometrial cancer were presented at 2026 SGO.
•
In May 2026, results of the Phase Ib/II clinical study of cadonilimab in combination with chemotherapy for the first-line treatment of advanced non-clear cell renal cell carcinoma (nccRCC) were presented as an oral presentation at 2026 ASCO. The cadonilimab combination demonstrated excellent tumor shrinkage and survival benefit potential across the entire patient population.
•
In March 2026, the Company entered into a collaboration with INOVIO (NASDAQ: INO) to jointly explore the potential of cadonilimab in combination with INOVIO’s novel DNA medicines for the treatment of glioblastoma.
The Company will continue to explore the clinical accessibility of cadonilimab in other indications, precisely identifying differentiated advantages over PD-(L)1, including benefits for all comers and addressing gaps in IO-resistant settings, thereby maximizing its clinical value and global commercial potential.
– 12 –
IO 2.0+ADC 2.0 Fully Initiated During the Reporting Period, the Company’s ADC technology platform accomplished significant progress. The IO 2.0+ADC 2.0 combination therapies officially entered the Phase II clinical stage, marking a major step forward in the Company’s strategic positioning in next-generation immuno-oncology combination therapies. The strategy aims to upgrade and improve therapies for multiple high incidence cancers around the world, such as lung cancer and breast cancer, and to continuously build a globally “nextgeneration” leading oncology therapy matrix. In the IO category, the Company is the only company globally with two approved oncology immunology bispecific antibodies. At the same time, the Company is promoting extensive combination therapies of ivonescimab and cadonilimab with a number of proprietary next-generation ADC 2.0 drugs. Ivonescimab and cadonilimab are both widely favored by global partners as the preferred choices for combination or breakthrough therapy exploration across various tumor types. In ADC therapies, the Company has developed a series of innovative next-generation ADC therapies, such as AK138D1 (HER3 ADC), AK146D1 (Trop2/Nectin4 ADC), AK157D1 (B7H3 ADC), AK158D1 (EGFR/Trop2 ADC). These ADC therapies are expected to overcome the common limitations of existing ADC drugs, such as narrow therapeutic window due to safety concerns, and provide enhanced efficacy, reduced toxicity, and overcome drug resistance that enables these ADC candidates to cover a broader range of indications. AK138D1 (HER3 ADC) is the Company’s first ADC drug to enter the clinical stage. In the first half of 2026, the Phase II clinical study of AK138D1 in combination with ivonescimab was formally initiated, with indications covering solid tumors including breast cancer and NSCLC. AK146D1 (Trop2/Nectin4 ADC) is the Company’s first bispecific ADC (BsADC) to enter the clinical stage. In the first half of 2026, the Phase II clinical study of AK146D1 in combination with ivonescimab was initiated, with indications covering solid tumors including breast cancer, NSCLC and urothelial carcinoma. In August 2026, AK157D1 (B7H3 ADC), the Company’s third ADC drug, received NMPA approval to enter clinical trial for advanced solid tumors. In July 2026, AK158D1 (EGFR/Trop2 ADC), the Company’s fourth ADC drug, was submitted for clinical trial application for advanced solid tumors.
– 13 –
ANNIKO® (penpulimab, PD-1) Penpulimab has a total of five approved indications in China, four of which are included in the latest version of the NRDL, including: •
For the treatment of relapsed or refractory classical Hodgkin lymphoma after at least two lines of systemic chemotherapy;
•
For the first-line treatment of locally advanced or metastatic squamous NSCLC;
•
For the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) failing at least two prior lines of systemic therapy;
•
For the first-line treatment of recurrent or metastatic NPC; and
•
For the first-line treatment of advanced hepatocellular carcinoma.
Penpulimab is also approved in the US for first-line recurrent or metastatic nonkeratinizing NPC, and for metastatic non-keratinizing NPC with disease progression on or after chemotherapy and with at least one other prior line of therapy. Ligufalimab (AK117, CD47) Ligufalimab is the world’s first CD47 monoclonal antibody to enter a registrational Phase III clinical study in solid tumors, and is in international clinical development in both solid tumors and hematological malignancies. Three Phase III clinical studies in solid tumors are enrolling patients China: •
Patient enrollment is ongoing in the Phase III clinical study (AK117-302) of ligufalimab combined with ivonescimab versus pembrolizumab for first-line treatment of recurrent/metastatic PD-L1 positive HNSCC.
•
Patient enrollment is ongoing in the Phase III clinical study (AK112-310) of ligufalimab combined with ivonescimab plus chemotherapy versus chemotherapy for first-line treatment of metastatic pancreatic cancer.
Global: •
The global multi-regional Phase III clinical study (ILLUMINE) of ivonescimab with or without ligufalimab versus pembrolizumab for first-line treatment of PD-L1 positive HNSCC is ongoing.
– 14 –
Three Phase II studies in hematologic malignancies are currently ongoing China: •
In June 2026, data from a randomized, double-blind, controlled Phase II study (AK117-206) of ligufalimab in combination with azacitidine and venetoclax for first-line treatment of acute myeloid leukemia (AML) were presented as an oral presentation at 2026 EHA.
•
The Phase I/II clinical study of ligufalimab in combination with AK129 (PD-1/ LAG-3) for the treatment of recurrent or refractory classical Hodgkin lymphoma (cHL) patients who have progressed after PD-(L)1 treatment is ongoing.
Global: •
Patient enrollment was completed in the global multi-regional Phase II clinical study of ligufalimab combined with azacitidine for first-line treatment of myelodysplastic syndrome (MDS).
New-Mechanism Clinical-Stage Products AK135 (IL-1RAP) is the Company’s first neuropathic pain management drug, with its Phase I clinical study for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) ongoing. Preclinical studies have shown that AK135 can significantly alleviate neuropathic pain while demonstrating good tolerability. AK150 (ILT2/ILT4/CSF1R) is the first trispecific antibody drug of the Company and the first trispecific in the world targeting these pathways. AK150 was developed using the Akeso’s AI- driven R&D platform and the Tetrabody multispecific platform of the Company. It received NMPA approval to enter clinical trials for malignant tumors in March 2026 and is currently in Phase I. AK154 (mRNA cancer vaccine), developed by the Company’s proprietary Flex-Nano mRNA technology platform, leverages AI algorithms to identify immunogenic mutations with high affinity. AK154 has been initiated in Investigator-Initiated Trials (IITs) in combination with ivonescimab/cadonilimab, with the aim of upgrading the “IO2.0+” strategy that integrates personalized oncology therapy with the Company’s IO bispecific antibodies.
– 15 –
CENTRAL NERVOUS SYSTEM (CNS) AND IMMUNOLOGY AND INFLAMMATION (I&I) THERAPEUTIC The Company is also strategically focusing on central nervous system and I&I diseases, building new high-potential therapies in these important and strategic indications. The therapeutic areas of CNS and I&I will benefit significantly from the development of bispecific antibody treatments. CNS AK152 (Aβ/TfR bispecific antibody) •
AK152 is the brain shuttle bispecific antibody new drug for Alzheimer’s disease (AD), and the first product in the R&D portfolio of the Company to advance to clinical stage in the CNS field. In November 2025, AK152 received NMPA approval to initiate clinical studies for AD. Preclinical results indicate that AK152 can effectively enhance brain penetration of the antibody and more rapidly clear Aβ plaques. The Phase I clinical trial is currently progressing smoothly. The Company has also proactively made subcutaneous formulation of this therapy, which is expected to further raise patient accessibility.
Metabolic 伊喜寧® (ebronucimab, PCSK9) 伊喜寧® has two approved indications in China, both of which are included in the latest version of the NRDL, including: •
For the treatment of primary hypercholesterolemia and mixed hyperlipidemia; and
•
For the treatment of heterozygous familial hypercholesterolemia.
In February 2026, the Company signed a cooperation agreement with JumpCan Pharmaceutical Group Co., Ltd. (濟川藥業集團有限公司) and Jiangsu Jiyuan Pharmaceutical Co., Ltd. (江蘇濟源醫藥有限公司) (collectively referred to hereinafter as “JumpCan Pharmaceutical”), both being wholly-owned subsidiaries of Hubei JumpCan Pharmaceutical Co., Ltd. (湖北濟川藥業股份有限公司) (Stock Code: 600566. SS), granting them the exclusive commercialization rights for 伊喜寧 ® in China (excluding Hong Kong, Macao, and Taiwan).
– 16 –
Immunology Immunology Bispecific Antibody AK139 (IL-4Rα/ST2) •
AK139 is the Company’s first bispecific antibody product in the immunology field and the world’s first IL-4Rα/ST2 bispecific antibody, developed by the Company’s proprietary AI platform. In February 2026, AK139 received NMPA approval to initiate a total of seven Phase II clinical studies covering indications including chronic obstructive pulmonary disease, severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic sinusitis with nasal polyps, moderate-to-severe atopic dermatitis and prurigo nodularis.
愛達羅® (ebdarokimab, IL-12/IL-23) •
In April 2025, the New Drug Application (NDA) for 愛達羅 ® for the treatment of moderate-to-severe plaque psoriasis was approved by the NMPA. In November 2025, this indication was included in the latest version of the NRDL.
奇佑康® (古莫奇單抗, IL-17) First NDA approved, one sNDA under NMPA review •
In June 2026, the NDA for gumokimab for the treatment of moderate-to-severe plaque psoriasis was approved by the NMPA.
•
In January 2026, the sNDA for gumokimab for the treatment of ankylosing spondylitis was accepted for review by the NMPA and is currently under review.
Manfidokimab (AK120, IL-4Rα) •
In February 2026, the NDA for manfidokimab for the treatment of moderate-tosevere atopic dermatitis was accepted for review by the NMPA and is currently under review.
•
The pivotal Phase III clinical study of manfidokimab for the treatment of a topic dermatitis in adolescents was completed.
The Company’s comprehensive and multi-dimensional product development and commercial strategy takes into account patient affordability, clinical unmet need, market accessibility, and competitive differentiation, to create therapies that can provide both meaningful improvement in patient outcomes and commercial value.
– 17 –
HUMAN RESOURCES As at June 30, 2026, we had a total of 4,082 employees. With the strategic goal of building our integrated platform of R&D, manufacturing and commercialization, the Company continues to recruit additional employees and upgrade the employee training and development system. The Company is committed to creating a diverse, fair, open and inclusive platform for employees. The following table sets forth the Company’s employees by function: Number of Number of employees employees as at as at June 30, 2026 June 30, 2025
Function R&D Pre-clinical R&D Clinical Manufacturing, Quality Assurance and Quality Control Sales and Marketing General and Administrative
326 745 924 1,652 435
329 720 864 1,221 395
Total
4,082
3,529
– 18 –
MANUFACTURING FACILITIES As at the date of this announcement, the Company has a production capacity of 110,000L, which can ensure large-scale supply capacity for the Company and its partners. The Company has a capacity expansion plan designed to support its future clinical development and commercial requirements. Our GMP compliant manufacturing facilities are designed and validated according to the FDA, the EMA, and the NMPA regulations to support the entire drug development and commercialization process. From drug discovery and process development to GMP-compliant commercial production, our manufacturing facilities support the Company’s clinical and commercialization development, as well as those of our global partners. Our key manufacturing facilities are highlighted below: Greater Bay Area Technology Park (Zhongshan): The site has facilities for biopharmaceutical R&D, production and sales, with a total planned production capacity of over 100,000L. The site has one of the most advanced biopharmaceutical manufacturing facilities in the world with a production capacity in operation of 55,000L as at the date of this announcement including 40,000L of stainlesssteel reactors and the advanced filling linkage system, and 15,000L of single-use bioreactors. Knowledge City Biopharmaceutical Base (Guangzhou): The production capacity in operation was 52,000L. National Health Technology Park (Zhongshan): The production capacity in operation was 3,000L.
– 19 –
FUTURE DEVELOPMENT Since 2026, the innovative drug industry in China has officially entered the internationalization 2.0 phase, characterized by source innovation-driven and globally collaborative R&D. Leveraging its global leadership in IO 2.0 and continuously innovative R&D capabilities, the Company is committed to addressing the core needs of patients worldwide, leveraging its six technology platforms and AI innovation platform, and actively promoting the realization of global clinical value for Chinese innovative drugs. Leading the Global IO 2.0 R&D Wave, Comprehensive IO 2.0+ADC 2.0 Combinations •
As the global leader in PD-1/VEGF, ivonescimab has become a critical IO 2.0 backbone therapy. Ivonescimab possesses multiple competitive advantages, including a significant first-mover advantage, a de-risked clinical profile that is validated by multiple approvals and registrational studies, and multiple clinical studies in solid tumors beyond NSCLC. Several data readouts from Phase III studies in China and globally have validated ivonescimab’s statistically significant and clinically meaningful survival benefits. These clinical studies show high consistency between global and Chinese patient data and demonstrates durable and meaningful long-term survival advantages. Recent statistically significant and positive Phase III OS results in BTC demonstrates ivonescimab’s treatment benefits beyond NSCLC. Global development across multiple additional indications and combination studies are currently ongoing.
•
The global multi-regional Phase III clinical study for cadonilimab in first-line gastric cancer and the global multi-regional registrational Phase II clinical study for second-line HCC have both been initiated. The Company plans to expand the global clinical accessibility of cadonilimab, with further exploration of other indications through collaborative development.
•
IO 2.0+ADC 2.0 Strategy: Phase II clinical studies of the Company’s selfdeveloped ADC drugs, AK138D1 (HER3 ADC) and AK146D1 (Trop2/Nectin4 ADC), in combination with ivonescimab/cadonilimab have been initiated for the treatment of NSCLC, breast cancer, urothelial cancer, etc. The Company also has two ADC assets that has recently entered the clinical stage, AK158D1(EGFR/Trop2 ADC) and AK157D1(B7H3 ADC).
– 20 –
AI Platforms & Six Therapeutic Technology for Drug Development Innovation We will continue to leverage our technological competitive advantage in complex biologics to expand our leadership in creating breakthrough therapies. By continuously innovating and combining novel targets with new mechanisms and platforms, we strengthen our ability to develop novel therapeutic combinations. We are actively building and optimizing our suite of platforms, with the AI drug R&D platform accelerating innovation across the entire R&D life cycle. These platforms include the Tetrabody antibody technology platform, Dual-Shield ADC technology platform, DualLock T-cell engager (TCE) technology platform, Tissue-Smart siRNA technology platform, Flex-Nano mRNA technology platform, and cell therapy technology platform. Our AI-driven integrated drug discovery platform covers the full spectrum of antibody and nucleic acid drug R&D and is expanding into emerging therapeutic frontiers. The deep integration of AI across key R&D domains further enhances and accelerates our leading position in the development of innovative and first-in-class therapies. Efficient Advancement of Global First-in-Class, High-Potential Blockbuster Molecules, Building “Next-Generation” Advantages We continue to advance a series of self-developed bispecific and multi-specific antibodies and other novel modalities covering oncology, CNS and I&I diseases. These include AK139 (IL-4Rα/ST2), AK152 (Aβ/TfR bispecific antibody), AK150 (ILT2/ ILT4/CSF1R), AK154(mRNA cancer vaccine), AK129 (PD-1/LAG-3), AK130 (TIGIT/ TGF-β), AK131 (PD-1/CD73), AK132 (Claudin18.2/CD47), and AK137 (CD73/LAG-3) which are being evaluated to address a broader range of indications. These efforts aims to address critical therapeutic areas worldwide with major unmet medical needs, while constructing a next-generation, leading and strategically positioned therapy matrix. We remain focused in executing our strategy of independent innovation and global development. We aspire to advance more of our self-developed innovative therapies through clinical development and regulatory registration in international markets, thereby translating Chinese innovation achievements for the benefit of patients worldwide. While actively advancing global clinical development of our therapies, we also continue to explore diverse collaboration opportunities, with the aim of creating combinations with innovators around the world.
– 21 –
FINANCIAL REVIEW 1.
Commercial Sales The Group’s total commercial sales, net of distribution cost increased by 28.65% from RMB1,401.6 million in the first half of 2025 to RMB1,803.2 million in the first half of 2026. The growth was primarily driven by significant sales contributions from two major immune bispecific antibody products in the oncology field, 開坦 尼 ® (cadonilimab, PD-1/CTLA-4) and 依達方 ® (ivonescimab, PD-1/VEGF). The Group’s marketing activities for commercialized products in non-oncology field are being progressively and orderly rolled out, with sales volume gradually increasing.
License Income In the first half of 2026, the Group’s license income was RMB2.5 million, compared to RMB9.9 million in the first half of 2025. This was generated from 普佑恒 TM (pucotenlimab, PD-1) licensed to Lepu Biopharma Co., Ltd. (stock code: 2157. HK) and 科泰萊 (tagitanlimab, PD-L1) licensed to Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Cost of Sales The Group’s cost of sales in the first half of 2026 was RMB465.2 million, and in the first half of 2025, it was RMB290.9 million. The increase was mainly attributable to the increased sales volume of two immune bispecific antibody products in oncology, 開坦尼 ® (cadonilimab, PD-1/CTLA-4) and 依達方 ® (ivonescimab, PD-1/VEGF), and the rise in the multi-channel cultivation of commercialized products in nononcology fields. Cost of sales of the Group mainly represents cost of raw materials, direct labor, equity incentive expenses, depreciation of plant and machinery and other manufacturing overhead.
Gross Profit The Group’s gross profit was RMB1,120.7 million in the first half of 2025 and RMB1,340.5 million in the first half of 2026.
– 22 –
Other Income and Gains, Net The Group’s other income and gains, net increased by 97.07% from RMB156.8 million in the first half of 2025 to RMB309.1 million in the first half of 2026, which was mainly due to the fluctuation in bank deposit interest income and bank investment product gains. The Group’s other income and gains, net primarily consisted of bank deposit interest income and subsidies. Subsidies include (i) subsidies specifically for capital expenditure in connection with the purchase of plant and machinery (recognized over the useful lives of the related assets); (ii) incentives and subsidies for research and development activities and others (recognized upon satisfaction of certain conditions); and (iii) awards granted without special conditions attached.
Research and Development Expenses During the Reporting Period, the Group’s research and development expenses increased by 7.12% year-on-year. In the first half of 2026, it was RMB783.3 million, accounting for 43.44% of sales revenue; in the first half of 2025, it was RMB731.2 million, accounting for 52.17% of sales revenue. The increase in R&D expenses during the Reporting Period was mainly due to the Group’s core product pipeline being in an intensive phase of Phase III clinical trials, and the new R&D platform also requiring continuous investment. The Group’s core pipeline development and NDA approvals achieved progress on multiple fronts, with multiple first-in-class or globally leading products achieving critical milestones and multiple R&D pipelines having achieved significant breakthroughs. The Group has a total of 29 products in the clinical research stage, with 12 products in Phase III clinical research stage and 17 products in Phase I/II clinical research stage. Among them, the Group has initiated over 60 clinical trials through combination therapies for ivonescimab, including over 40 indications. Cadonilimab is approved or in clinical studies for over 20 indications and over 40 clinical trials have been initiated in China and overseas. Ligufalimab is the world’s first CD47 monoclonal antibody to enter a registrational Phase III clinical study in solid tumors, and is in international clinical development in both solid tumors and hematological malignancies. AK139 is the Group’s first bispecific antibody product in the immunology field and received NMPA approval to initiate a total of seven Phase II clinical studies. AK152 is the first brain shuttle bispecific antibody new drug for Alzheimer’s disease (AD), and the first product in the R&D portfolio of the Company to advance to clinical stage in the CNS field. The Phase I clinical trial is currently progressing smoothly. In ADC therapies, the Group has developed a series of innovative next-generation ADC therapies, such as AK138D1 (HER3 ADC), AK146D1 (Trop2/Nectin4 ADC), AK157D1 (B7H3 ADC), AK158D1 (EGFR/Trop2 ADC), which entered the clinical stage or the Phase II clinical study in succession.
– 23 –
The Group possesses full-chain research and development capabilities. Its independently conducted R&D activities include but are not limited to: drug research and development, process development, clinical development, clinical operations, data statistics, pharmacovigilance, and clinical pharmacology. The main research and development expenses primarily consisted of: (i) employee salaries and related benefit costs in connection with our research and development activities; (ii) third-party contracting costs relating to testing expenses for pre-clinical programs; (iii) costs associated with purchasing raw materials for research and development of our drug candidates; and (iv) clinical trial sites fees, central laboratory bioanalysis fees, third-party assessment fees, costs associated with purchasing reference listed drugs and concomitant drugs, third-party contract fees signed by clinical trial site management service providers and other trial related service providers. 7.
Selling and Marketing Expenses The Group’s selling and marketing expenses in the first half of 2026 amounted to RMB785.6 million, representing 43.56% of commercial sales revenue, compared to RMB669.9 million or 47.80% of commercial sales revenue, in the first half of 2025. This rate decreased by 4.24%, mainly benefiting from the continuous growth of commercial sales revenue and the ongoing improvement in commercial operating efficiency. During the Reporting Period, commercial sales revenue increased by 28.65% year-on-year. The Group’s selling and marketing expenses are mainly used for the academic promotion activities and multi-channel market development activities of two major immune bispecific antibody products, 開坦尼® (cadonilimab, PD-1/CTLA-4) and 依 達方® (ivonescimab, PD-1/VEGF); as well as brand building, academic promotion, and market development activities for commercialized products in non-oncology fields; and the establishment of the Group’s commercial operation team and the execution of commercial operation systems.
Administrative Expenses The Group’s administrative expenses were RMB134.0 million in the first half of 2025 and RMB169.6 million in the first half of 2026. The increase was mainly due to the growth in equity incentive expenses to promote the Company’s long-term development strategy as well as maintain and continuously improve the Group’s operational efficiency. The Group’s administrative expenses primarily consisted of employee salaries and benefits, depreciation and amortization expenses, professional fees, taxes and other administrative expenses including travel expenses and other expenses associated with administrative activities.
– 24 –
Finance Costs The Group’s finance costs decreased by 0.13% from RMB63.4 million in the first half of 2025 to RMB63.3 million in the first half of 2026. The decrease was mainly due to the reduction of borrowing interest rates.
- Profit/Loss for the Period The Group recorded a loss of RMB447.2 million in the first half of 2026, as compared to a loss of RMB588.3 million in the first half of 2025. The loss decreased by RMB141.0 million compared to the same period last year. The reduction in this loss is mainly attributable to:
During the Reporting Period, the proportion of the Group’s selling and marketing expenses to commercial sales revenue decreased by 4.24% year-on-year. In the first half of 2026, selling and marketing expenses accounted for 43.56% of commercial sales revenue, compared to 47.80% in the first half of 2025.
In accordance with IFRS, the Group accrued equity investment losses on Summit Therapeutics (NASDAQ: SMMT) based on the loss amount and shareholding ratio of Summit Therapeutics (NASDAQ: SMMT) during the Reporting Period, which decreased by 40.45% year-over-year. In the first half of 2026, the accrued amount for this investment loss was RMB114.2 million. The provision for this investment loss in the first half of 2025 was RMB191.7 million, and the provision for this investment loss decreased by RMB77.5 million.
- Liquidity and Source of Funding and Borrowing In the first half of 2026, we actively expanded financing channels, controlled financing costs, continuously improved the Group’s operational capabilities and efficiency, and ensured the long-term stable development and strategic goals of the group with abundant cash reserves. As at June 30, 2026, the Group’s current assets were RMB11,461.9 million, comprising RMB9,160.0 million in cash, cash equivalents, time deposits, and financial products, with other current assets amounting to RMB2,301.9 million. As at June 30, 2026, the Group’s current liabilities were RMB2,861.3 million, which included RMB688.8 million in trade payables, RMB1,188.4 million in other payables and accruals, and RMB974.7 million in interest-bearing bank and other borrowings.
– 25 –
As at June 30, 2026, the Group had short-term loan and mid-long-term loan due within next one year of RMB974.7 million and long-term loans of RMB3,990.2 million, among which, interest rate of commercial bank borrowings ranges from 1.0% to 3.2% based on annual interest rate below loan prime rate (LPR). The Group follows a conservative set of funding and treasury policies to manage its capital resources and mitigate potential risks. 12. Pledge of Assets As at June 30, 2026, the Group had a total of RMB1,831.7 million of buildings and land use right pledged to secure its loans and banking facilities. 13. Key Financial Ratios The following table sets forth the key financial ratios for the dates indicated:
Quick ratio(1) Gearing ratio(2)
As at June 30, 2026
As at December 31, 2025
3.62 Not meaningful(2)
4.71 Not meaningful(2)
Notes: (1)
Quick ratio is calculated by dividing current assets less inventories as at a given date by current liabilities as at such date.
(2)
Gearing ratio is calculated using interest-bearing bank and other borrowings less cash and cash equivalents divided by total equity and multiplied by 100%. Gearing ratio is not meaningful as our interest-bearing bank and other borrowings less cash and cash equivalents were negative.
- Significant Investments As at June 30, 2026, the Group did not hold any significant investments. Except as disclosed in this announcement, the Group did not have other plans for significant investments or capital assets as at the date of this announcement.
- Material Acquisitions and Disposals The Group did not have any acquisitions or disposals of subsidiaries, associates and joint ventures in the first half of 2026.
– 26 –
- Contingent Liabilities The Group did not have any material contingent liabilities as at June 30, 2026.
- Capital Commitments The capital commitments of the Group as at June 30, 2026 were RMB560.0 million, as compared to RMB263.1 million as at December 31, 2025. This was primarily attributable to the development of world-class manufacturing equipment in order to increase production capacity in Knowledge City Biopharmaceutical Base (Guangzhou). Concurrently, construction continues at the Shanghai R&D Center and the Guangzhou R&D Center.
- Foreign Exchange Risk Exposure In the first half of 2026, the Group mainly operated in China and the majority of its financial transactions were settled in RMB, the functional currency of the Company’s primary subsidiaries. As at June 30, 2026, a portion of the Group’s cash and cash equivalents were dominated in Hong Kong dollars and US dollars. Except for certain cash and cash equivalents, time deposits, financial products, other receivables, payables, other payables and accrued expenses denominated in foreign currencies, the Group did not have significant foreign exchange risk exposure from its operations during the Reporting Period. The Group currently does not have a foreign currency hedging policy. However, we manage our foreign exchange risk by performing regular reviews of our net foreign exchange exposure, and may potentially use forward contracts to eliminate the foreign exchange risk exposures if such needs arise.
- Employees and Remuneration As at June 30, 2026, the Group had a total of 4,082 employees. The total remuneration cost incurred by the Group was RMB870.4 million in the first half of 2026, and RMB733.2 million in the first half of 2025. The increase in remuneration cost was primarily attributable to the increase in the number of employees and the grant of RSUs and Share Options, which led to an increase in employees’ salaries and benefits.
– 27 –
The remuneration of the employees of the Group comprises salaries, bonuses, employees’ provident fund and social security contributions, other welfare payments and equity-settled share award and share option expenses. In accordance with applicable PRC laws, the Group has made contributions to social security insurance funds (including pension plans, medical insurance, work related injury insurance, unemployment insurance and maternity insurance) and housing funds for the Group’s employees. We provide training and development programs to employees, including new hire orientation and continuous on-the-job training in order to maintain and improve the knowledge and skill levels of our employees. The Group adopted the Pre-IPO RSU Scheme on August 29, 2019. For details, please refer to the section headed “D. Share Incentive Schemes — 1. Restricted Share Unit Scheme” in Appendix IV to the Prospectus. The Pre-IPO RSU Scheme was terminated in accordance with the rules of the Pre-IPO RSU Scheme on June 30, 2024. For details, please refer to the announcement of the Company dated June 5, 2024 and the circular of the Company dated June 6, 2024, respectively. After the termination of the Pre-IPO RSU Scheme, no further awards might be granted thereunder, while the awards already granted before the termination shall remain valid and continue to vest in accordance with the rules of the Pre-IPO RSU Scheme. The Group also adopted the 2021 RSU Scheme on December 6, 2021. For details, please refer to the announcement of the Company dated December 7, 2021. The 2021 RSU Scheme was amended on June 30, 2024. For details, please refer to the announcement of the Company dated June 5, 2024 and the circular of the Company dated June 6, 2024, respectively. The Group also adopted the Share Option Scheme on June 28, 2022. For details, please refer to the circular of the Company dated June 1, 2022. The Share Option Scheme was amended on June 30, 2024. For details, please refer to the announcement of the Company dated June 5, 2024 and the circular of the Company dated June 6, 2024, respectively. The Group also adopted the Share Option Scheme on May 24, 2025. For details, please refer to the circular of the Company dated May 26, 2025. The Group also granted Share Options and RSUs on July 24, 2026. For details, please refer to the announcement of the Company dated July 26, 2026.
– 28 –
OTHER INFORMATION INTERIM DIVIDEND The Board does not recommend the payment of an interim dividend to the Shareholders for the Reporting Period (six months ended June 30, 2025: Nil). CORPORATE GOVERNANCE PRACTICES The Directors recognize the importance of good corporate governance in management and internal procedures to achieve effective accountability. The Company has applied the principles of the Corporate Governance Code and adopted the code provisions set out in part 2 of the Corporate Governance Code as its own code to govern its corporate governance practices. The Company has complied with all code provisions set out in the Corporate Governance Code throughout the Reporting Period with the exception of code provision C.2.1. Under code provision C.2.1 of the Corporate Governance Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Under the current organizational structure of the Company, Dr. XIA Yu is the chairwoman and chief executive officer of the Company. With her extensive experience in the industry, the Board believes that vesting the roles of both chairwoman and chief executive officer in the same person provides the Company with strong and consistent leadership, allows for effective and efficient planning and implementation of business decisions and strategies, and is beneficial to the business prospects and management of the Group. Although Dr. XIA Yu performs both the roles of chairwoman and chief executive officer, the division of responsibilities between the chairwoman and chief executive officer is clearly established. In general, the chairwoman is responsible for supervising the functions and performance of the Board, while the chief executive officer is responsible for the management of the business of the Group. The two roles are performed by Dr. XIA Yu distinctly. We also consider that the current structure does not impair the balance of power and authority between the Board and the management of the Company given the appropriate delegation of the power of the Board and the effective functions of the independent non-executive Directors. However, it is the longterm objective of the Company to have these two roles performed by separate individuals when suitable candidates are identified. The Board will continue to review and monitor the practices of the Company with an aim of maintaining a high standard of corporate governance.
– 29 –
MODEL CODE FOR SECURITIES TRANSACTIONS The Company has adopted the Model Code as its own code of conduct regarding dealings in the securities of the Company by the Directors and senior management who, because of his/her office or employment, is likely to possess inside information in relation to the Company or its securities. Upon specific enquiry, all Directors confirmed that they had complied with the Model Code throughout the Reporting Period. In addition, the Company is not aware of any non-compliance of the Model Code by the senior management of the Group throughout the Reporting Period. PURCHASE, SALE OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company’s listed securities during the Reporting Period. REVIEW OF INTERIM RESULTS BY THE AUDIT COMMITTEE The Audit Committee, comprising Mr. TAN Bo, Dr. XU Yan and Dr. ZENG Junwen, has jointly reviewed with the management the accounting principles and policies adopted by the Company and discussed internal control and financial reporting matters (including the review of the unaudited interim condensed consolidated financial information of the Group for the Reporting Period). The Audit Committee considered that the unaudited interim condensed consolidated financial results for the Reporting Period are in compliance with the relevant accounting standards, laws and regulations, and the Company has made appropriate disclosures thereof. The interim condensed consolidated financial information of the Group for the Reporting Period has not been audited. The Company’s independent auditor, Ernst & Young, has performed an independent review of the Group’s interim financial information for the Reporting Period in accordance with Hong Kong Standard on Review Engagements 2410 Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Hong Kong Institute of Certified Public Accountants. EVENTS AFTER THE REPORTING PERIOD The Company granted RSUs under the 2021 RSU Scheme and Share Options under the Share Option Scheme on July 24, 2026. For details, please refer to the announcement of the Company dated July 26, 2026. Save as disclosed above, as at the date of this announcement, the Group had no significant events after the Reporting Period.
– 30 –
PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT This announcement is published on the website of the Stock Exchange at www.hkexnews.hk and the website of the Company at www.akesobio.com. The interim report of the Company for the Reporting Period containing all the information required by the Listing Rules will be dispatched (if necessary) to the Shareholders and published on the above websites in due course.
– 31 –
INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME For the six months ended 30 June 2026
Notes
Six months ended 30 June 2026 2025 RMB’000 RMB’000 (Unaudited) (Unaudited)
Commercial sales License income
1,865,881 2,458
1,401,622 9,917
Total income from commercial sales and licenses Less: distribution cost
1,868,339 (62,658)
1,411,539 –
1,805,681
1,411,539
Cost of sales
(465,182)
(290,863)
Gross profit
1,340,499
1,120,676
309,085 (783,326) (785,554) (169,615)
156,837 (731,236) (669,939) (133,966)
(114,158) (177,502) (63,324)
(191,697) (75,208) (63,360)
(443,895)
(587,893)
(3,351)
(385)
(447,246)
(588,278)
171,697
34,825
REVENUE
3
Other income and gains, net Research and development expenses Selling and marketing expenses Administrative expenses Share of loss of a long-term equity investment — Summit Therapeutics Inc. Other expenses, net Finance costs
4
LOSS BEFORE TAX Income tax expense
5
LOSS FOR THE PERIOD OTHER COMPREHENSIVE (LOSS)/INCOME Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods: Exchange differences on translation of foreign operations
– 32 –
Notes
Other comprehensive (loss)/income that will not be reclassified to profit or loss in subsequent periods: Translation from functional currency to presentation currency Equity investment designated at fair value through other comprehensive income: Change in fair value
Six months ended 30 June 2026 2025 RMB’000 RMB’000 (Unaudited) (Unaudited)
(369,661)
(36,146)
(11,133)
11,460
(380,794)
(24,686)
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, NET OF TAX
(209,097)
10,139
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD
(656,343)
(578,139)
Loss attributable to: Owners of the parent Non-controlling interests
(424,220) (23,026)
(570,081) (18,197)
(447,246)
(588,278)
(633,317) (23,026)
(559,942) (18,197)
(656,343)
(578,139)
Basic
RMB(0.46) yuan
RMB(0.64) yuan
Diluted
RMB(0.46) yuan
RMB(0.64) yuan
Total comprehensive loss attributable to: Owners of the parent Non-controlling interests
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT
7
– 33 –
INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION 30 June 2026 30 June 2026 RMB’000 (Unaudited)
31 December 2025 RMB’000 (Audited)
4,028,628 318,171 17,268
3,880,371 318,640 19,057
23,226
23,327
–
31,622
250,063 119,326
315,919 134,234
4,756,682
4,723,170
1,104,870 966,359 230,718
931,616 1,021,666 152,361
470,761 8,689,205
349,213 8,822,414
11,461,913
11,277,270
688,817 1,188,439 974,739 9,311
451,847 1,151,109 585,668 6,503
Total current liabilities
2,861,306
2,195,127
NET CURRENT ASSETS
8,600,607
9,082,143
TOTAL ASSETS LESS CURRENT LIABILITIES
13,357,289
13,805,313
Notes NON-CURRENT ASSETS Property, plant and equipment Right-of-use assets Intangible assets Financial assets at fair value through profit or loss Equity investment designated at fair value through other comprehensive income Long-term equity investment — Summit Therapeutics Inc. Other non-current assets Total non-current assets CURRENT ASSETS Inventories Trade receivables Prepayments, other receivables and other assets Financial assets at fair value through profit or loss Cash and bank balances
8
Total current assets CURRENT LIABILITIES Trade payables Other payables and accruals Interest-bearing bank and other borrowings Lease liabilities
– 34 –
9
30 June 2026 RMB’000 (Unaudited)
31 December 2025 RMB’000 (Audited)
NON-CURRENT LIABILITIES Interest-bearing bank and other borrowings Contract liabilities Lease liabilities Deferred income Deferred tax liabilities Other liabilities
3,990,169 559,716 10,479 371,221 70 64,151
3,954,853 572,627 9,001 322,725 150 –
Total non-current liabilities
4,995,806
4,859,356
Net assets
8,361,483
8,945,957
EQUITY Equity attributable to owners of the parent Share capital Shares held for restricted share unit schemes Reserves
65 (152,857) 8,639,238
65 (48,604) 9,096,433
8,486,446
9,047,894
Non-controlling interests
(124,963)
(101,937)
Total equity
8,361,483
8,945,957
– 35 –
INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS For the six months ended 30 June 2026 Six months ended 30 June 2026 2025 RMB’000 RMB’000 (Unaudited) (Unaudited) Net cash flows from/(used in) operating activities
290,277
(227,505)
Net cash flows used in investing activities
(735,574)
(1,740,921)
Net cash flows from financing activities
246,670
505,561
NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents at beginning of period Effect of foreign exchange rate changes, net
(198,627) 1,279,827 (27,293)
(1,462,865) 2,915,742 (21,824)
CASH AND CASH EQUIVALENTS AT END OF PERIOD
1,053,907
1,431,053
– 36 –
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 30 June 2026 1.
CORPORATE INFORMATION The Company was incorporated in the Cayman Islands as an exempted company with limited liability on 30 January 2019. The address of the registered office of the Company is Floor 4, Willow House, Cricket Square, Grand Cayman KY1-9010, Cayman Islands. The Company is an investment holding company. The Company’s subsidiaries were involved in research and development, production and sale of biopharmaceutical products. The shares of the Company were listed on the Main Board of the Stock Exchange of Hong Kong Limited (the “Stock Exchange”) on 24 April 2020.
2.1 BASIS OF PREPARATION The unaudited interim condensed consolidated financial information for the six months ended 30 June 2026 has been prepared in accordance with IAS 34 Interim Financial Reporting issued by the International Accounting Standards Board. The unaudited interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2025. The unaudited interim condensed consolidated financial information is presented in Renminbi (“RMB”) and all values are rounded to the nearest thousand except when otherwise indicated. 2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group’s annual consolidated financial statements for the year ended 31 December 2025, except for the adoption of the following amended IFRS Accounting Standards for the first time for the current period’s financial information. Amendments to IFRS 9 and IFRS 7 Amendments to IFRS 9 and IFRS 7 Annual Improvements to IFRS Accounting Standards — Volume 11
Amendments to the Classification and Measurement of Financial Instruments Contracts Referencing Nature-dependent Electricity Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7
The above amendments did not have any material impact on the interim condensed consolidated financial information.
– 37 –
REVENUE AND OPERATING SEGMENT INFORMATION Revenue An analysis of revenue is as follows: Revenue from contracts with customers (a)
Disaggregated revenue information Six months ended 30 June 2026 2025 RMB’000 RMB’000 (Unaudited) (Unaudited) Types of goods or services Commercial sales License income
1,865,881 2,458
1,401,622 9,917
Total income from commercial sales and licenses Less: Distribution cost
1,868,339 (62,658)
1,411,539 –
Revenue
1,805,681
1,411,539
Timing of revenue recognition Transferred at a point in time Transferred over time
1,615,267 190,414
1,333,576 77,963
Revenue
1,805,681
1,411,539
Distribution cost is relevant to the product sales, and it represents the distribution fee paid or payable by the Group to customers. The following table shows the amounts of revenue recognised in the current reporting period that were included in the contract liabilities at the beginning of the reporting period and recognised from performance obligations satisfied in previous periods: Six months ended 30 June 2026 2025 RMB’000 RMB’000 (Unaudited) (Unaudited) 66,855
Product sales
– 38 –
32,875
(b)
Performance obligations Information about the Group’s performance obligations is summarised below: Revenue from license income The performance obligation is satisfied at a point in time when the customer obtains the rights to the underlying technology. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognises revenue at a point in time when the related sales occur. Sale of products The performance obligation is satisfied upon delivery of the products and payment is generally due within 1 year from delivery. Some contracts provide customers with sales rebates which give rise to variable consideration subject to constraint. Revenue from provision of services The performance obligation is satisfied over time as services are rendered and payment is generally due upon completion of the services, except for new customers, where payment in advance is normally required.
Other segment information The Group is engaged in research, development, production and sale of biopharmaceutical products, which is regarded as a single reportable segment in a manner consistent with the way in which information is reported internally to the Group’s senior management for purposes of resource allocation and performance assessment. Therefore, no analysis by operating segment is presented. Geographical information Non-current assets As at 30 June 2026 RMB’000 (Unaudited)
As at 31 December 2025 RMB’000 (Audited)
Chinese mainland USA Other regions
4,483,389 250,063 4
4,352,294 315,921 6
Total
4,733,456
4,668,221
The non-current asset information above is based on the locations of the assets and excludes financial instruments.
– 39 –
OTHER INCOME AND GAINS, NET Other income and gains, net Six months ended 30 June 2026 2025 RMB’000 RMB’000 (Unaudited) (Unaudited) Bank interest income Investment income from financial products Net changes in fair value of financial assets Grants released* Value-added tax credits Others
148,404 726 8,971 33,700 115,589 1,695
126,011 4,343 7,432 18,786 – 265
Total
309,085
156,837
Grants mainly represent subsidies obtained from external sources for research activities and awards related to capital expenditure incurred on certain projects.
INCOME TAX The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate. Pursuant to the rules and regulations of the Cayman Islands and the BVI, the Group is not subject to any income tax in the Cayman Islands or the BVI. The subsidiary incorporated in Hong Kong was subject to Hong Kong profits tax at the rate of 16.5% (six months ended 30 June 2025: 16.5%) on any estimated assessable profits arising in Hong Kong. No provision for Hong Kong profits tax has been made as the Group has no assessable profits derived from or earned in Hong Kong during the six months ended 30 June 2026 (six months ended 30 June 2025: Nil). The provision for corporate income tax in the Chinese mainland is based on the statutory rate of 25% of the assessable profits in accordance with the PRC Corporate Income Tax Law, which was approved and became effective on 1 January 2008, except for certain subsidiaries which were qualified as High and New Technology Enterprises and were subject to a preferential income tax rate of 15% for the six months ended 30 June 2026 and 2025. The subsidiary incorporated in the USA was subject to United States federal and California income taxes at rates of 21% and 8.84%, respectively, for the six months ended 30 June 2026 and 2025. During the period, California income tax was provided at the rate of 8.84% on the estimated assessable profits arising in the USA. The subsidiary incorporated in the Australia is subject to Australian income tax. Australian corporate income tax has been provided at the rate of 30% on the estimated assessable profits arising in Australia.
– 40 –
The income tax expense of the Group is analysed as follows: Six months ended 30 June 2026 2025 RMB’000 RMB’000 (Unaudited) (Unaudited)
Current-profits tax Charge for the period Deferred
3,431 (80)
397 (12)
Total tax charge for the period
3,351
385
DIVIDEND No dividend has been paid or declared by the Company during the six months ended 30 June 2026 and subsequent to the end of the reporting period (six months ended 30 June 2025: Nil).
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT The calculation of basic loss per share amounts is based on the loss for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 918,644,386 (six months ended 30 June 2025: 895,180,342) outstanding during the period. For the six months ended 30 June 2026 and 2025, as the Group incurred losses, no adjustment has been made to the basic loss per share amount in respect of a dilution as the impact of the restricted share units and share options had no dilutive effect on the basic loss per share amount. The calculations of basic and diluted loss per share are based on: Six months ended 30 June 2026 2025 RMB’000 RMB’000 (Unaudited) (Unaudited) Loss Loss attributable to ordinary equity holders of the parent, used in the basic and diluted loss per share calculation
(424,220)
(570,081)
Number of shares Six months ended 30 June 2026 2025 (Unaudited) (Unaudited) Shares Weighted average number of ordinary shares outstanding during the period used in the basic and diluted loss per share calculation
– 41 –
918,644,386
895,180,342
TRADE RECEIVABLES 30 June 2026 RMB’000 (Unaudited)
31 December 2025 RMB’000 (Audited)
Trade receivables
970,595
1,027,508
Impairment
(4,236)
(5,842)
Total
966,359
1,021,666
Included in the Group’s trade receivables is an amount due from a non-controlling shareholder of a subsidiary of the Group of RMB156,530,000 (31 December 2025: RMB32,641,000). An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:
30 June 2026 RMB’000 (Unaudited)
31 December 2025 RMB’000 (Audited)
Within 3 months 3 to 6 months 6 to 9 months 9 to 12 months Over 1 year
844,506 74,331 36,070 – 11,452
996,507 13,707 11,452 – –
Total
966,359
1,021,666
TRADE PAYABLES An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows: 30 June 2026 RMB’000 (Unaudited)
31 December 2025 RMB’000 (Audited)
Within 3 months 3 to 6 months 6 months to 1 year Over 1 year
367,503 44,376 41,320 235,618
162,623 48,176 4,296 236,752
Total
688,817
451,847
The trade payables are non-interest-bearing and are normally settled on terms of within 90 days except for the balances due to a non-controlling shareholder of a subsidiary of the Group of RMB320,018,000 (31 December 2025: RMB278,916,000), which are repayable on demand.
– 42 –
DEFINITIONS In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings. “2021 RSU Scheme”
the restricted share unit scheme adopted by the Company on December 6, 2021 and amended on June 30, 2024
“AACR”
American Association for Cancer Research
“ASCO”
American Society of Clinical Oncology Annual Meeting
“Audit Committee”
audit committee of the Board
“Board”
board of Directors
“CDE”
the Center for Drug Evaluation of NMPA (中華人民共和 國國家藥品監督管理局藥品評審中心)
“China” or “PRC”
the People’s Republic of China, which, for the purpose of this announcement and for geographical reference only, excludes Hong Kong, the Macau Special Administrative Region and Taiwan
“CMC”
chemistry, manufacturing and controls processes, including manufacturing techniques, impurities studies, quality controls and stability studies
“Company”
Akeso, Inc. (康方生物科技(開曼)有限公司), an exempted company with limited liability incorporated under the laws of the Cayman Islands on January 30, 2019
“CRO”
contract research organization
“Corporate Governance Code”
Corporate Governance Code set out in Appendix C1 to the Listing Rules
“CSCO”
Chinese Society of Clinical Oncology Annual Meeting
“Director(s)”
director(s) of the Company
“EHA”
European Hematology Association
“EMA”
European Medicines Agency
– 43 –
“ESGO”
European Society of Gynaecological Oncology
“FDA”
Food and Drug Administration of the United States
“GMP”
good manufacturing practice
“Group”, “we”, “us” or “our” the Company and all of its subsidiaries, or any one of them as the context may require or, where the context refers to any time prior to its incorporation, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it “Hong Kong”
the Hong Kong Special Administrative Region of the PRC
“IND”
investigational new drug or investigational new drug application, also known as clinical trial application in China
“Listing Rules”
the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
“Model Code”
Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
“NDA”
new drug application
“NMPA”
the National Medical Product Administration of the PRC (中華人民共和國國家藥品監督管理局)
“NRDL”
National Reimbursement Drug List managed by the National Healthcare Security Administration of the PRC (中華人民共和國國家醫療保障局)
“OS”
overall survival
“PFS”
progression-free survival
“Pre-IPO RSU Scheme”
the restricted share unit scheme adopted by the Company on August 29, 2019 and terminated on June 30, 2024
– 44 –
“Prospectus”
the prospectus of the Company dated April 14, 2020
“R&D”
research and development
“Same Period Last Year”
the six months ended June 30, 2025
“Reporting Period”
the six months ended June 30, 2026
“RMB”
Renminbi, the lawful currency of the PRC
“RSU(s)”
restricted share unit(s) granted under the 2021 RSU Scheme
“SGO”
Society of Gynecologic Oncology
“Share(s)”
ordinary share(s) with a nominal value of US$0.00001 each in the share capital of the Company
“Share Option(s)”
share options granted under the Share Option Scheme
“Share Option Scheme”
the share option scheme adopted by the Company on June 28, 2022 and amended on June 30, 2024
“Shareholder(s)”
holder(s) of the Share(s)
“sNDA”
supplemental new drug application
“Stock Exchange”
The Stock Exchange of Hong Kong Limited
“SUMMIT”
Summit Therapeutics Inc., a company incorporated under the law of the State of Delaware, the United States, and whose shares are listed on Nasdaq (NASDAQ: SMMT)
“Tetrabody”
a portmanteau of the phrase “tetravalent antibody”, which refers to our proprietary technology for the design and production of innovative tetravalent bispecific antibodies (with four antigen-binding sites in each antibody molecule)
“United States” or “US”
the United States of America, its territories, its possessions and all areas subject to its jurisdiction
– 45 –
“US$”
United States dollars, the lawful currency of the United States
“%”
per cent By order of the Board Akeso, Inc. Dr. XIA Yu Chairwoman and executive Director
For identification purposes only
Hong Kong, August 27, 2026 As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive Director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive Directors, Mr. XIE Ronggang as non-executive Director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive Directors.
– 46 –
2026-08-26
HONG KONG, Aug. 25, 2026 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that a pre-specified interim analysis assessed by the Independent Data Monitoring Committee (IDMC) of the randomized, controlled, double-blinded, multicenter, registrational Phase III clinical study (AK112-309/HARMONi-GI1) of ivonescimab in combination with chemotherapy versus durvalumab (PD-L1 monoclonal antibody) in combination with chemotherapy for the first-line treatment of advanced biliary tract cancer (BTC), showed that the study met its primary endpoint of overall survival (OS), achieving a clinically meaningful and statistically significant positive result. The study also met all key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR).
Detailed results from this study will be presented at an upcoming international academic conference and published in a peer-reviewed journal.
Durvalumab in combination with chemotherapy is currently the preferred first-line immunotherapy regimen recommended by international guidelines and is regarded as the optimal standard of care (SOC). HARMONi-GI1 is the first Phase III study in biliary tract cancer to demonstrate a statistically significant positive OS result versus the global gold standard (PD-L1 monoclonal antibody plus chemotherapy), representing a major milestone in the treatment of this difficult disease.
Dr. Michelle Xia, Founder, Chairwoman, President and CEO of Akeso:
"We are delighted the Phase III clinical study of ivonescimab in combination with chemotherapy versus durvalumab in combination with chemotherapy for the first-line treatment of biliary tract cancer has achieved a statistically significant positive OS result. This is a major breakthrough for the treatment of biliary tract cancer.
We sincerely thank the investigators, study teams, and patients who made HARMONi-GI1 possible. Their important contributions bring us closer to an innovative, safe, and highly effective new treatment option against this aggressive cancer.
The positive result of HARMONi-GI1 marks the first positive Phase III study for ivonescimab in gastrointestinal tumors, following four positive Phase III results in lung cancer. The breakthrough clinical value of ivonescimab is now expanding from lung cancer to a broader range of solid tumors. We look forward to making this innovative therapy available to patients worldwide as soon as possible."
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multispecific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.
Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
2026-08-21
HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The clearance allows initiation of a Phase I study in patients with advanced malignant solid tumors. Development of AK157D1 in combination with Akeso's proprietary bispecific antibodies ivonescimab and cadonilimab is also planned.
AK157D1 is the third next-generation ADC candidate from Akeso to enter clinical development, following AK146D1 (TROP2/Nectin-4 ADC) and AK138D1 (HER3 ADC). The clearance further advances the Company's IO2.0 + ADC2.0 strategy and expands its broad innovative oncology pipeline.
B7-H3 is highly expressed in a broad range of solid tumors, including non-small cell lung cancer, small cell lung cancer, prostate cancer, esophageal cancer, nasopharyngeal carcinoma, colorectal cancer, breast cancer, and glioblastoma, with limited expression in normal tissues. This profile supports its potential as a broad-spectrum antitumor target.
AK157D1 was developed entirely in-house and incorporates a proprietary design. In preclinical studies, it has shown potent antitumor activity together with a favorable safety profile. These attributes may help address certain limitations associated with existing ADCs, including hematologic toxicity and interstitial lung disease, and support its continued development as a potential ADC of choice in both mono or combination therapies.
Akeso is advancing its IO2.0 + ADC2.0 strategy, built on proprietary bispecific and multispecific antibody technology and centered on cornerstone IO2.0 assets including ivonescimab and cadonilimab. Through this approach, the company is elevating treatment standards for major cancers worldwide and building a broad oncology portfolio to create next-generation standard of care.
In the immuno-oncology field, Akeso has two approved bispecific antibodies for cancer treatment. The Company is actively evaluating ivonescimab and cadonilimab in combination with its proprietary next-generation ADC candidates. Increasingly, global partners recognize both ivonescimab and cadonilimab as preferred agents for combination regimens and breakthrough therapy explorations across a wide spectrum of tumor types. In the ADC space, Akeso has built a differentiated pipeline of next-generation candidates, including AK146D1 and AK138D1, which are already in clinical development, and AK157D1 and AK158D1 (a bispecific ADC), which are anticipated to enter the clinic shortly. These agents are designed to address the narrow therapeutic window and safety limitations commonly associated with first-generation ADCs.
About AK157D1
AK157D1 is a novel B7-H3-targeting ADC independently developed by Akeso. Preclinical studies have demonstrated potent antitumor activity and a favorable safety profile.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached commercial stage.
Through efficient and groundbreaking R&D, Akeso integrates premier global resources to develop transformative medicines, deliver high-quality, affordable therapeutic antibodies to patients worldwide, and generate sustained commercial and societal value as it strives to become a global leader in biopharmaceutical innovation.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Akeso, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| MEMA | 0.46% | 5,000 | $ 57.339K | Aug 31, 2026 |
| TMED | 0.39% | 8,000 | $ 90.078K | Jun 30, 2026 |
| DFSE | 0.05% | 27,000 | $ 294.793K | Nov 12, 2026 |
| DFEM | 0.03% | 242,000 | $ 2.642M | Nov 12, 2026 |
| DFAE | 0.03% | 233,000 | $ 2.544M | Nov 12, 2026 |
| DFAX | 0.01% | 160,000 | $ 1.747M | Nov 12, 2026 |
| AVEM | 0.01% | 456,000 | $ 3.683M | Nov 16, 2026 |
| JSTC | 0.01% | 3,970 | $ 32.435K | Nov 17, 2026 |